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Problem: Adolescents and young adults (AYA) ages 13 to 24 comprise a quarter of the new 
HIV diagnoses in the United States. Lack of access to HIV-preventive therapies such as pre-
exposure prophylaxis (PrEP) reduces opportunities to prevent HIV infection in this population. 
Initiating PrEP in AYA significantly reduces the negative health outcomes of HIV, but it is 
evident that many clinicians are still reluctant to initiate PrEP in AYA patients based on 
perceived threats and barriers. 
Context: Primary care clinics, including school-based clinics, have an opportunity to offer HIV 
prevention services including PrEP. This project, the Adolescent and Young Adult 
Comprehensive PrEP Education Project (AYA ComPrEP) is an HIV-prevention quality 
improvement project that is directed towards providing AYA high-risk populations with 
access to PrEP in the primary care setting. The project was supposed to be completed at 
the Balboa Teen Clinic of Balboa High School, a clinic serviced by the Community 
Health Programs for Youth (CHPY) of the San Francisco Department of Public Health 
(SFDPH). Due to the COVID-19 pandemic shelter-in-place policy, the training for clinicians 
and staff, and roll out of PrEP service for adolescent clients of Balboa Teen Clinic was deferred 
to an unknown date. An online training and simulation for the University of San Francisco 
clinicians (nurse practitioner students) was conducted instead.  
Interventions: A site feasibility analysis was conducted, which include consultations with 
CHPY leadership and management, site assessment, conduct of face-to-face in-depth interviews 
among staff of Balboa Teen Clinic, and review of literature and best practices to develop 
recommendations for a pilot PrEP program for AYA. Some interventions were modified to 
focus on increasing the confidence of providers, nurse practitioners students of the 
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University of San Francisco (USF) to prescribe PrEP to AYA. The focus of this DNP 
project was shifted to designing modules, conducting and evaluating of an online simulation, a 
PrEP training workshop for providers. The simulation include didactic, role play, case studies 
covering information, best practice recommendations on HIV and AIDS, HIV counseling, 
reproductive health, sexual orientation and gender identity initiative, and PrEP for AYA.  
Measures: A pre-assessment and post-simulation evaluation was utilized to determine the 
change in providers’ knowledge, enabling attitudes, confidence, and readiness to offer HIV 
prevention services, and prescribe PrEP in preparation for their integration in clinics that they 
will be working. Case studies in the form of simulated patients to measure how they would apply 
the knowledge and confidence gained towards real life practice scenarios. 
Results: Nineteen clinicians attended the online PrEP simulation training-workshop. The data 
analysis revealed a 17.11% increase in HIV/AIDS & PrEP knowledge mean score (average 
scores: 76% for pre-simulation versus 89% for post-simulation) among participants. Likewise, 
HIV and PrEP enabling or non-stigmatizing attitude scores has increased by 18.3% (average 
scores: 71% for pre-simulation versus 84% for post-simulation). All the 19 clinicians revealed 
that their knowledge and confidence to prescribe PrEP to adolescents and young adults in their 
practice has increased as a result of attending the simulation (13 strongly agreed; 6 agreed) as 
compared to 2 clinicians prior to the simulation. 
Conclusions: PrEP targeted for at-risk AYA is necessary to reduce HIV rates. This is possible 
by breaking barriers to PrEP prescription through education and training of clinicians. PrEP 
should be included in the training and preparation of clinicians to address the adolescent and 
young adult populations. Online simulation training workshop for PrEP is an effective alternative 
means if face-to-face training is not possible. 




Background and Problem Description  
Human immunodeficiency virus (HIV) infection has claimed millions of lives across the 
world (UNAIDS, 2019). The Joint United Nations Program on HIV & AIDS (UNAIDS) and the 
World Health Organization (WHO) estimates that 36.9 million people worldwide were living 
with HIV in 2017 (UNAIDS, 2019). In the United States in 2017, the Centers for Disease 
Control and Prevention (CDC) reported 38,739 new HIV diagnoses, with an estimate of 
1,100,000 people of all ages currently living with HIV in the U.S. (CDC, 2018). Around 15% 
(one out of seven) people living with HIV in the country are not aware that they are infected 
(CDC, 2018). More than half of the new HIV infections were from the southern part of the 
country. The annual rate of new HIV diagnoses in the U.S. has decreased compared to a decade 
ago, but for the last several years (2012-2016) has remained stable rather than decreasing. The 
CDC has indicated that this is due to inadequate outreach to those who could most benefit, 
primarily disproportionately affected populations in the south such as African Americans and 
Latinos/Hispanics (CDC, 2018).  
Adolescents and young adults aged 13 to 24 represent approximately 15% of the U.S. 
population according to U.S. Census Bureau (2017). In 2015, at least 22% of new HIV diagnoses 
in the U.S. were among adolescents and young adults (AYA) between the ages of 13 and 
24 (CDC, 2018). Men having sex with men (MSM) constituted the gender group with the most 
substantial number of new HIV infections (81%) among young people. Lack of access to PrEP 
prophylaxis reduces the opportunity to prevent HIV infection in this population (Hosek et al., 
2016). Approximately half of AYA, particularly adolescents and young men having sex with 
men (AYMSM), have poor health outcomes with low retention in care, and low viral-load 
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suppression (CDC, 2018). Acquiring HIV at a young age means lifelong management of chronic 
HIV infection. This has economic and psychosocial implications for every individual infected by 
HIV, for society, and for public health practice worldwide. The lifetime cost per patient for HIV 
care in 2018 in the U.S. was $485,000 (CDC, 2020). 
HIV is a virus that weakens the immune system by destroying certain types of white 
blood cells called CD4-T cells (also known as CD4 cells). These lymphocytes help to coordinate 
an immune response by invoking B cells (which produce antibodies), as well as macrophages, 
and other types of T cells that also fight infection (U.S. HHS, 2019). The virus is spread through 
certain body fluids including semen, vaginal fluids, blood, and breast milk. When HIV enters the 
body, it takes three weeks to three months for the body to develop HIV antibodies that can be 
detected through an HIV antibody test (HAT). It takes around 3-4 weeks for a newly infected 
person to seroconvert from HIV negative to HIV positive, a condition which the person may or 
may not experience an acute viral illness. When a person is infected with HIV, the virus destroys 
CD4 cells, reducing them to low levels, inhibiting immune protection, and increasing viral load 
levels. As a result, the infected person is more susceptible to opportunistic infections such as 
tuberculosis, toxoplasmosis, pneumonia and certain types of cancers such as Kaposi’s sarcoma 
(CDC, 2018). HIV infection is primarily spread through anal and vaginal sex, as well as shared 
needles or syringes, a common practice among people who inject drugs (CDC, 2018). Other 
modes of transmission such as mother-to-child and needle stick injury are less common in the 
U.S., and while there is a risk, it is extremely rare cases to contract HIV through oral sex or 
blood transfusion (CDC, 2018). Improved health care, including access to HIV services, harm 
reduction programs such as needle exchange services, and PrEP play a role in the reduction of 
HIV transmission in western countries including the U.S. (CDC, 2018).  
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In the three decades since the first wave of the epidemic, various interventions have 
emerged to improve strategies for preventing HIV, including the use of pharmaceuticals for pre-
exposure prophylaxis (PrEP). Among adolescents, HIV infections still continue at a high rate 
(CDC, 2018) despite increased programs targeting key populations through HIV education and 
the availability of preventive medications (PrEP), as well as post-exposure prophylaxis (PEP) 
and other effective antiviral treatment for people living with HIV.  
What is PrEP?  
 Pre-exposure prophylaxis (PrEP) for HIV includes medications and other delivery 
devices that prevent HIV transmission. Currently, Truvada™ and Descovy™ are the only two 
pharmaceutical interventions in oral form that shown in clinical trials to prevent HIV 
transmission that has approval by the FDA (CDC, 2019). Other methods of PrEP include other 
delivery devices such as injections, implants, and vaginal rings. They are still under clinical 
trials. This medication, Truvada™, is a combination tenofovir disoproxil fumarate (TDF) and 
emtricitabine (FTC). These drugs have been used effectively to manage HIV infection since 
1996 and are known for their safety profile together and in combination with other forms of anti-
retroviral drugs (e.g. efavirenz) as treatment for HIV infection. In 2012, Truvada™ was found 
through clinical trials to be more than 90% effective in preventing sexual transmission of HIV 
among high-risk HIV-negative populations such as men who have sex with men, and 70% 
effective for those who inject drugs. PrEP is relatively safe and the CDC (2019) reports that no 
significant side effects have been seen in HIV-negative persons who have been taking PrEP for 
up to 5 years. However, potentially serious side effects of Truvada that warrant monitoring 
include kidney problems, lactic acidosis, severe liver problems, and bone loss (Gilead Sciences, 
2019). It is recommended that HIV-negative persons be tested for kidney and liver function and 
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that healthcare providers rule out hepatitis infection and bone problems before prescribing 
continuous Truvada.  
PrEP as a pharmacologic intervention, became available for adult men who have sex with 
men (MSM) was initiated in July 2012 when the U.S. Federal Drug Administration (FDA) 
approved Truvada® taken once daily to prevent the sexual transmission of HIV. Though the U.S. 
is the first country to implement PrEP, data reveals that from 2012 to 2015, a meager percentage 
of PrEP prescriptions (7.6%) were provided for youth under the age of 25 (Bush et al., 2016). 
Limited clinician knowledge and comfort in the use of PrEP, along with the absence of FDA 
indications for PrEP use in this population prior to 2018 have contributed to the low rate of new 
PrEP prescriptions in young people (Hosek et al., 2016). Likewise, some providers lack 
awareness of statutes allowing treatment of adolescents for sexually transmitted infections (STI) 
prevention without parental notifications, and limited adolescence-focused healthcare services 
reduce the use of PrEP among this group. 
The patent for Truvada expired in December 2017 and other countries have ruled against 
the extension of patency rights of Truvada, making it available for overseas pharmaceutical 
companies to create generic versions of Truvada (TDF/FTC) to be used as pre-exposure 
prophylaxis. This reduces the cost of Truvada to approximately $10 per bottle in countries such 
as Australia, significantly lower than the cost in the U.S., where the medication has been priced 
at $2,000 per bottle. Currently, the original manufacturer, Gilead has a program to waive co-pays 
to those who are taking anti-retroviral medications both for non-positive patients (PrEP) and 
those living with HIV (in treatment).  
New PrEP Formulation. In October 2019, the FDA approved a safer version of 
tenofovir, the tenofovir alafenamide or TAF in combination with emtricitabine or FTC known as 
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Descovy™ for cisgender males (men who have sex with men and transgender women). It is 
found to be equally effective to Truvada but less toxic and has fewer side effects, particularly in 
kidney functions and bone demineralization (Krakower, Daskalakis, Feinberg, Marcus, 2020). 
The result from the study of 5,300 cisgender men who have sex with men and transgender 
women in North America and Europe revealed that HIV pre-exposure prophylaxis regimen 
utilizing Descovy™ was found to be superior to the traditional regimen with Truvada™ with 
more than 90% effectiveness (Schoen, J., 2019).   
Alternative PrEP Dosing. Daily adherence to PrEP remains a challenge to some patients 
and consequently to providers. PrEP providers face issues prescribing PrEP and at the same time 
ensuring adherence and avoiding viral resistance to Truvada. In other parts of the world such as 
France, the UK, Canada, and Australia, alternative dosing to daily PrEP is available. Some of the 
alternative PrEP dosing evaluated in various studies (Appendix A) across the world includes on-
demand PrEP, event-driven PrEP, time-driven PrEP, and intermittent PrEP. While this may not 
yet be widely practiced in the United States and is limited to studies, alternative PrEP dosing 
may become more available in later years. In a Kenyan study, Mutua et al (2012) suggested that 
adherence to intermittent dosing may be more difficult than adherence to daily dosing, but still 
may be effective in preventing HIV infection if minimum effective concentrations of the drug are 
attained. In the latest Paris study of Molina et al (2018), intermittent dosing has shown similar, 
successful profiles in comparison with daily dosing. The Prevenir ANRS study in Paris has high 
retention rates with good safety profiles for both intermittent and daily PrEP groups (Molina et 
al., 2018). Alternative dosing of PrEP has the potential to minimize costs, decrease toxicity or 
adverse events, improve adherence, and increase HIV prevention in populations with alternative 
PrEP IN ADOLESCENTS AND YOUNG ADULTS 
 
13 
lifestyles such as those working in the sex trade, recreational drug users, and the homeless (Volk 
et al., 2012).  
It is important that clinicians are up to date with new information, research, and practices 
provided by the guidelines. Insight into maintaining effectiveness of HIV prevention using a 
daily dosing regimen of PrEP or alternative dosing will facilitate understanding of what 
constitutes a safe and acceptable PrEP intake. This could lead to change and stronger policies 
and protocols that support alternative dosing of Truvada, particularly in settings with limited 
resources and in populations for whom daily PrEP pill intake remains an issue.  
Clinical Practice Guidelines on PrEP  
The CDC released the first interim guidance for the use of preventive medication (PrEP), 
in 2012, in sexually active adult MSM who are at substantial risk of acquiring HIV infection 
(CDC, 2014). The risk for HIV is based on patterns of anal sex, use of condoms, multiple 
partners, monogamous relationships, HIV status of a partner, and positive diagnosis of sexually 
transmitted infection (CDC). In May 2014, the United States Public Health Service released the 
first clinical practice guidelines for daily oral pre-exposure prophylaxis (PrEP) (CDC). This was 
updated in 2016 and 2017, which included revisions to several sections of the guidelines. The 
latest 2017 updates did not change the recommendation for the use of PrEP in the U.S; rather it 
included a call for the development of evidence-based studies and clarification on specific points 
in clinical care (CDC, 2018). For example, a preference for antigen/antibody testing whenever 
available, rather than antibody-only tests, is now recommended. Also, the use of a 3, 000 
copies/mL cut-off for suspected false-positive viral load tests was set (CDC, 2018). The CDC 
(2018) added information on hepatitis C screening in relation to PrEP to be consistent with the 
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guidance of the 2017 American Association for the Study of Liver Diseases (AASLD) and the 
Infectious Disease Society of America (IDSA). 
The current CDC guidelines for men who have sex with men (MSM) were found to 
reduce the incidence and prevalence of HIV infection in the U.S. Projecting the data forward, 
based on the study by Jennesse et al. (2016), a 40% coverage of PrEP for MSM in the U.S. could 
potentially prevent 1,162 new infections per 100,000 persons (33% of infections). In the study of 
Goodreau et al. (2017), initiating PrEP for adolescent sexual minority males six months after 
their first anal sex at 40% coverage among this group is projected to prevent 27.8% of HIV 
infections. Despite the effectiveness of PrEP in preventing the transmission of HIV, the U.S. 
registers low utilization of Truvada (CDC, 2018). Local health departments and public health 
clinics across the U.S. were the main source of prescriptions for Truvada, however, PrEP 
implementation remains at very low rates (Weiss, Smith, Newman, Wiener, Kitlas, Hoover, 
2018).  
Low utilization or the lack of taking Truvada for those who are at risk is seen by those 
who are significantly impacted by recent HIV infections, African Americans and Latinos, the 
populations that account for the highest proportions of new HIV infections in the U.S (CDC, 
2019). Despite accounting for 13% of the total population in the U.S., African Americans had a 
43% (16,694) of the 38,739 new HIV diagnoses in 2017 (CDC). The majority (60%) of the new 
infections among African Americans were gay and bisexual men, while a quarter (26%) were 
among women. Yet of the 78,360 persons who filled prescriptions for Truvada™ in the U.S. in 
2016, only 11.2% were African American while and only 13.1% were Hispanic, compared to 
68.7% white. Although there was a 5% decrease in new HIV infections in African Americans 
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from 2010 to 2016 among gay and bisexual men ages 13-24, there was an increase of 40% in 
new HIV infections among African Americans ages 25-34 (CDC, 2019). 
Problem Description 
PrEP in San Francisco 
The San Francisco Department of Public Health first implemented a PrEP program in 
2012, when Truvada™ was approved as an HIV-prevention pill. Young people in San 
Francisco have had access to PrEP since 2016, as an off-label medication through the clinics 
of the Community Health Programs for Youth (CHPY). Cole Street Clinic and Larkin Street 
Clinic, two CHPY facilities, have been providing PrEP as an off-label prescription to its most-
at-risk AYA patients based on the judgment of the clinician and the circumstances of the 
patients. Factors in prescribing PrEP typically include insurance coverage for Truvada and 
ease of PrEP delivery, but not necessarily the emerging risks of the patient. As of 2018, in a 
landmark achievement, the FDA increased access to PrEP for patients under age 18. This new 
guideline aims to provide opportunities for clinicians to prescribe PrEP for at risk AYA (CDC 
2014).  
HIV Prevalence in San Francisco 
In San Francisco, aggressive collective efforts are paying off with record-low number of 
new HIV cases. The SFDPH is a major partaker in the ‘Getting to Zero’ initiative of the World 
Health Organization and the United Nations and will benefit from this project. This ambitious 
initiative aims to achieve zero new HIV infections, zero HIV deaths, and zero HIV-related 
stigma by 2020. It is San Francisco’s vision to reduce HIV transmission and HIV-related deaths 
by 90% in 2020 as part of this initiative. The City and County of San Francisco have been 
performing well in recent years to meet the target, outpacing national efforts to reduce HIV 
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infection with only about 221 reported cases in 2017, reported by SFDPH Population Health 
Division (2018). This was achieved by providing access to HIV medications for people living 
with HIV and PrEP for high-risk persons. The latest 2017 HIV data records the lowest number of 
new HIV cases for San Francisco since the HIV epidemic in the 1980s (SFDPH Population 
Health Division, 2018). The face of San Francisco’s HIV epidemic reflects more Caucasian 
whites in higher numbers as compared to African Americans and Latinos, which is reflective of 
the national epidemic.  
Risk Among Youth and Young Adults. Since 2014, San Francisco public health 
efforts have been directed toward reducing HIV transmission among young people who are 
most at risk (SFDPH Population Health Division, 2018). In 2017, of the 221 new HIV 
infections in San Francisco, more than 60% are younger than 40 years old (SFDPH Population 
Health Division, 2018). Over 100 of the people living with HIV who reside in the city are ages 
13-24 as of December 2017 (SFDPH Population Health Division, 2018).  
HIV in the African American Community. Despite low numbers of new HIV 
infections within San Francisco, the annual rate of new HIV shows an increase among African 
Americans in 2017, with African American men reaching triple times higher rates of HIV than 
of white men. Rates were also eight times higher for African American women than Caucasian 
women (SFDPH Population Health Division, 2018). Public health efforts to engage African 
American men in prevention programs hopes to curb these increases and bring rates to a lower 
level in this group.  
Needs within the Homeless Population. While PrEP and HIV treatment for people 
living with HIV in San Francisco is available, there is the need for better services and outreach 
programs for homeless people; many are adolescents and young adults. Currently, less than a 
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third of homeless people living with HIV are virally suppressed (SFDPH Population Health 
Division). Issues of safe storage of medications and mental health or substance abuse disorders 
that affect treatment play a role in reaching the city goal for zero new HIV infection by 2020 
(SFDPH Population Health Division). Our best opportunity at this time is to make PrEP 
accessible to everyone, with emphasis on the needs of vulnerable populations, which include 
young people, African Americans, Hispanic, and the homeless.   
Adolescent and Young Adult Access to PrEP in San Francisco 
The Community Health Programs for Youth (CHPY) is part of the San Francisco Health 
Network (SFHN) in the San Francisco Department of Public Health (SFDPH). Comprised of 
more than eight major and satellite specialty clinics across San Francisco, CHPY provides 
comprehensive clinical services for adolescents and young adults (AYA) age 12-25, including 
those who are transgender and homeless (SFHN, 2018).  
An estimated 15,952 are people living with HIV in San Francisco with 221 new cases in 
2017. Around 11% of new HIV infections in 2017 occurred in ages 13-24, with 18% in ages 25-
29 years old, and 33% in ages 30-39 years old (SFDPH Population Health Division, 2018). 
CHPY provides medical services to young people living with HIV in the city, particularly the 
homeless, through its Larkin Street Clinic and Cole Street Clinic. CHPY works in partnership 
with the Larkin Youth Services to give medical care through its ACAC (Assisted Care-After 
Care Program) HIV Specialty Clinic to young people living with HIV, housed in a residential 
program facility on Hyde Street.  
Currently, there is no standard assessment template in the electronic record that CHPY 
clinicians can use to do risk assessment and identify PrEP candidates. Sexual history and other 
risk behavior assessments are being performed inconsistently based on the observation of this 
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author. Enrollment in PrEP is merely based on the clinician’s individual judgment or 
preference or at the patient’s request (although we know from the literature that a significant 
percentage of young people are unaware of the availability of PrEP). There is a significant 
need to make PrEP available to more at-risk AYA patients of CHPY utilizing a standardized 
approach. Assessment of the perceived roles of CHPY nurses in PrEP education for youth is 
also needed to understand the challenges of PrEP delivery and to improve clinical and nursing 
practices with regard to PrEP.   
The adolescent group at CHPY is a diverse population. Some adolescents are men having 
sex with men, others are sexually active transgender, or adolescents who engage in sex work 
and/or drug use. The complexity of this age group for PrEP delivery is worth understanding. 
Protocols should exist to inform primary care providers and to support these at-risk populations 
in navigating the healthcare system to better address their HIV prevention needs. Adoption of the 
CDC guidelines for AYA MSM (Goodreau et al., 2017) could reduce the high rate of HIV 
infections in this age group. Based on the consultations and interviews, not all staff and primary 
care team members at CHPY are aware of the updated CDC PrEP guidelines and protocol. The 
current CDC guidelines could be adopted and modified to address the relevance of PrEP for at-
risk adolescents, highlighting the role of clinicians and other members of the healthcare team, 
including nurse practitioners and nurses. 
Available Knowledge: Barriers to PrEP as a Preventive Service for AYA 
Literature Search. A comprehensive literature search on barriers to PrEP utilization was 
performed using CINAHL Complete, PubMed, Fusion, EBSCO, and Cochrane with the date 
range January 1, 2012, to June 1, 2019. The author chose these dates because Truvada® and the 
PrEP intervention protocol became available in 2012. The initial search using the terms 
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“nursing” and “HIV prevention” yielded around 145 articles. Further inclusion criteria provided 
access to studies in the biomedical sciences on preventing HIV. The author applied the following 
search terms across all databases: PrEP, pre-exposure prophylaxis, barriers, adolescents, nursing, 
and clinicians, which yielded approximately 65 published papers. Barriers were classified as 
either prescriber-associated barriers, or AYA patient-associated barriers. Although only U.S. 
studies were included in the review, studies from other countries and those involving different 
age groups were used as a basis of reference to verify the findings of this evaluation.  
Evaluation of the Evidence. Nine articles met the inclusion criteria and were selected 
for final review. The evidence was rated using the John Hopkins Nursing Evidence-Based 
Practice Appraisal Tool. The table in the Appendix B present the evidence assessed in this 
review, categorized according to provider-associated and patient-associated barriers in AYA 
PrEP use. All of the examined evidence provided explicit aims, findings on barriers to AYA 
PrEP use, and recommendations for application in clinical practice and for future research. Due 
to the limited number of studies available specifically on barriers to AYA PrEP use, the author 
included articles with both high quality (Rating A) as well as those of with good quality (Rating 
B). The appraisal rating of B was given to study results that do not appear to be generalizable, 
due to the small sample size or other limitations (Refer to Appendix B).  
The articles on PrEP services that were selected for review included four studies 
emphasizing the attitudes of PrEP prescribers (i.e. physicians or nurse practitioners). Despite the 
small sample size of the clinician studies, they provide an in-depth understanding of providers’ 
viewpoint, intentions, practices, and response to the CDC PrEP guidelines.  
Clinician Barriers to PrEP as Preventive Service for AYA 
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Drawing on research experience and data, recommendations for the modification of 
existing PrEP guidelines can be developed to benefit adolescents and young adults at risk of HIV 
infection. Tables in the Appendix A provide a synopsis on barriers to PrEP use in adolescents 
and young adults, categorized according to 1) provider-associated barriers in AYA PrEP use and; 
2) AYA patient-associated barriers. Studies involving clinicians included a total of 233 providers 
who had experience with medications used for PrEP. Mullins et al looked at the attitudes of 
clinicians toward the CDC PrEP guidelines (Mullins, Lally, Zimet, & Kahn, 2015), attitudes of 
providers towards PrEP (Mullins, Zimet, Lally, & Kahn, 2016), the relationship between 
intention to prescribe PrEP and actual prescription (Mullins, Zimet, Lally, Xu, Thornton et al, 
2017), and youth access to PrEP in relation to providers willingness to prescribe PrEP to youth 
(Hart-Cooper, Allen, Erwin, & Scott, 2018). 
Clinicians’ attitudes toward AYA using PrEP. Study findings reveal that clinicians 
reported greater intention to prescribe PrEP to adults as compared with adolescents (Mullins et 
al, 2015). Providers faced challenges in prescribing PrEP to AYA, particularly those below 18 
years of age, due to lack of clarity that PrEP falls under protected confidential care for 
adolescents, which does not require parental consent (Mullins et al, 2016). Concern about 
maintaining confidentiality and involvement of parents of AYA is common among providers. 
The majority of clinicians are not concerned about the off-label use of PrEP for those below 18. 
However, clinicians have differing views about adolescence patients’ ability to understand PrEP 
benefits and risks and give true informed consent (Mullins et al). Issues on maintaining 
confidentiality and parental involvement were common among providers. A significant number 
of providers expressed a lack of clarity that PrEP falls under protected confidential care for 
adolescents, which does not require parental consent (Mullins et al, 2016). 
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Providers are concerned about patient adherence to the PrEP daily medication schedule, 
attendance at monitoring visits, the development of viral resistance due to incomplete adherence, 
participation in behavioral interventions such as counseling or group work, side effects of the 
medication, toxicity (e.g. effects on bone density and renal function), and financial difficulties 
(Mullins et al, 2015). These concerns were identified as common barriers to PrEP prescription. 
Perceived high cost of insurance was associated with reduced intention to prescribe PrEP to 
AYA (Mullins et al, 2016). There is also a concern about risk compensation: the possibility that 
patients might participate in riskier behaviors since they felt protected from HIV infection 
because they utilize PrEP (Mullins et al, 2016). Some prescribers are concerned about negative 
publicity and the negative attitudes of colleagues toward PrEP, particularly in prescribing PrEP 
to patients who are below 18 years of age (Mullins et al).  
Willingness to Prescribe PrEP. The CDC guidelines recommend PrEP for those who 
have ongoing high risk of HIV acquisition and are able to metabolize prophylactic medications, 
(indicated by a creatinine clearance greater than or equal to 60 mL per minute) (CDC, 2012). 
Women at high risk for HIV are considered appropriate for the drug if they are not breastfeeding. 
Those who are at high risk such as men having sex with men (MSM), having multiple sex 
partners, or not using condoms are good candidates for PrEP. Clinicians in general were aware of 
the CDC interim guidelines on PrEP; however, some practices diverged from the guidelines, and 
clinicians attempted to construct their own operational definition of who qualify for PrEP based 
on the patients that they encounter in their practice (Mullins et al, 2015).  
Mullins et al (2015), found that almost all clinicians (80%) were willing to prescribe 
PrEP for those who are long-term partners of persons living with HIV. Among clinicians, at least 
60% were also willing to prescribe PrEP for those engaged as sex workers. Of the 162 providers 
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across the U.S. who participated in the study willingness to prescribe PrEP was strongly 
associated with the belief that providers had enough knowledge to safely provide PrEP to 
adolescents and young adults (Hart-Cooper, et al, 2018). Although almost all providers agreed 
that PrEP prevents HIV, not all were willing to prescribe PrEP to young adults (77.8%) and even 
few willing to prescribe to adolescents (64.8%). A history of prescribing non-occupational post-
exposure prophylaxis (nPEP) was associated with actual prescription of PrEP (Mullins et al, 
2017). Post-exposure prophylaxis is HIV preventive medication given within 72 hours after HIV 
exposure such as sexual contact. 
Clinicians felt that engaging in unsafe sexual behaviors (MSM, transgender, and high-
risk heterosexuals) does not automatically warrant PrEP prescription, although these factors do 
trigger an assessment for PrEP. Providers described characteristics of people who would not be 
appropriate for PrEP, including those with: 1) the presence of a mental health diagnosis, and/or 
2) substance abuse issues (Mullins et al, 2017). These presentations are also perceived as 
indicators of a person engaging in higher risk sexual behavior, but with major issues likely to 
negatively impact adherence to PrEP.  
Barriers in Adolescents and Young Adults to PrEP Preventive Services 
A summary of the barriers to AYA PrEP use from the AYA patient perspective is 
demonstrated in Table 2 (Appendix B). The five studies included in the review looked at the 
awareness of PrEP among AYA, their attitudes toward PrEP, social behavioral influences, 
likelihood to participate in a PrEP adherence study, willingness to take PrEP, safety and 
implementation issues, and adherence. More than 500 participants were included in these studies, 
which include AYMSM, and transgender male and female adolescents.  
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Lack of PrEP awareness. In a study of male adolescents and young males who have sex 
with men by Perez-Figueroa et al (2015) revealed that approximately 50% have an awareness of 
PrEP. Some compared taking PrEP to taking birth control (a form of medication that prevents an 
unwanted outcome with just a pill a day). For others, the consistency required by a PrEP regimen 
could be problematic. Consequently, despite of the awareness of PrEP, study participants 
expressed hesitation about PrEP use. AYMSM desired more information about PrEP including 
side effects, various types of drug regimens, active ingredients in the medications, and the odds 
of contracting HIV while on PrEP (Perez-Figueroa et al). In transgender male and female AYA, 
half of the study respondents indicated they would probably participate in a PrEP adherence 
study (Fisher et al, 2017). In the study of Holloway et al (2017), the willingness to take PrEP 
among AYMSM is significantly associated with the time since their last HIV test, their level of 
concern about becoming infected with HIV, recent receptive condomless anal sex, the use of 
illicit drugs in the past six months, and their HIV risk index score.  
Negative attitudes toward PrEP. For some AYMSM, PrEP is one of several strategies 
to protect themselves from acquiring HIV other than condoms. However, they viewed taking 
daily medication as harder to remember than using condoms (Perez-Figueroa et al, 2015). In a 
transgender study (Fisher et al, 2017), a quarter (23%) did not want to add another medication to 
their health regime. Regardless of age and gender, about half of participants were extremely 
worried about the negative side effects of PrEP.  One-third were concerned about getting to 
quarterly appointments (Fisher et al). Likewise, increased medical mistrust was associated with 
decreased willingness to take PrEP among AYMSM (Holloway et al, 2017). However, not all 
adolescents and young males who have sex with men are concern about getting HIV. YMSM 
less concerned about the risk of getting HIV were twice as unlikely to be willing to take PrEP as 
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compared to YMSM who had medium or high concern of acquiring the infection (Holloway et 
al).  
Economics. Taking PrEP medications entails financial burden, particularly for those who 
have no insurance or have no access to PrEP subsidy programs. Young men of color often voiced 
concerns about the cost of PrEP (Holloway et al, 2017). 
Adherence and retention. For some, the consistency required by a PrEP regimen could 
be problematic. They viewed taking daily medication as harder to remember than using condoms 
(Perez-Figueroa et al, 2015). One-third were concerned about getting to quarterly appointments 
(Fisher et al). Adherence to PrEP is viewed by AYMSM as difficult in the long term. AYA were 
concerned about missing pills, developing resistance to PrEP, and contracting HIV, as well as 
side effects (Perez-Figueroa et al, 2015). Greater concern about adherence was associated with 
decreased willingness to take PrEP in AYMSM (Holloway et al, 2017). In a measure of 
adherence study among youth in PrEP by Koss et al (2018), adherence to PrEP use waned over 
time in AYA, particularly after week 12. Self-reporting in a PrEP protocol overestimates actual 
adherence by young people (Koss et al). The most common reasons for missing doses of PrEP 
were: 1) being away from home; 2) being too busy; 3) forgetting; and 4) changes in routine 
(Hosek et al, 2017). 
The stigma of PrEP. In general, stigma towards HIV is a barrier to HIV prevention and 
PrEP is not an exception. Some AYMSM viewed PrEP negatively as a preventive strategy for 
those who engage in high-risk sexual behaviors or more frequent casual encounters (Perez-
Figueroa et al, 2015). Use of PrEP was viewed as a trust and fidelity issue, i.e. taking PrEP could 
mean the likelihood that the individual will have sex outside the primary relationship (Perez-
Figueroa et al, 2015). However, some reasoned that if their partners were having sex outside of 
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the relationship, PrEP could serve as a protection (Perez-Figueroa et al). Holloway et al (2017) 
reveals that YMSM who were unwilling to take PrEP had concerns about stigma, in addition to 
questions about drug effects, risk compensation, medical mistrust, adherence, access, and 
affordability. Increased medical mistrust was associated with decreased willingness to take PrEP 
in AYMSM (Holloway et al, 2017). Other participants questioned the necessity of taking PrEP.  
Other barriers. Not all adolescents and young males who have sex with men show 
concern about getting HIV. YMSM less concerned about the risk of getting HIV were twice as 
unlikely to be willing to take PrEP as compared to YMSM who had medium or high concern that 
they might acquiring the infection (Holloway et al, 2017). Other participants questioned the 
necessity of taking PrEP. The willingness to take PrEP among AYMSM is significantly 
associated with the time since their last HIV test, their level of concern about becoming infected 
with HIV, recent receptive condomless anal sex, the use of illicit drugs in the past six months, 
and their HIV risk index score Holloway et al, 2017). 
Rationale 
 The focus of this project was preventative health services, specifically in 
community and public health organizations targeting underserved populations. Creating 
an adolescent-friendly primary care environment that makes PrEP available to 
adolescents and young adults at risk can reduce barriers to effective HIV prevention . The 
goal is to minimize, if not eliminate, new HIV infections in this cohort in San Francisco 
through a comprehensive educational package of PrEP and HIV prevention.  
Working with the Community Health Programs for Youth in the SFDPH, the AYA 
ComPrEP was designed to create a PrEP program for Balboa Teen Clinic by enhancing 
and standardizing CHPY’s PrEP provision practices, existing PrEP guidelines, and 
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adopting them for Balboa. To support clinician services, the project includes a needs 
assessment and training workshop on recent HIV research and guidelines, the 
development of an HIV-risk screening tool, templates for the electronic health record 
(EHR), and PrEP management protocol, as well as web-based and hard copy resources for 
providers and staff. The objective was to conduct an education and training session to 
increase confidence for medication prescription and counseling for PrEP/HIV in 
clinicians and staff to increase PrEP utilization and uptake in the appropriate at risk 
patients.  
Conceptual Framework 
Two models, one the Diffusion of Innovation theory and the other, Awareness 
Adherence model, were applied to increase PrEP initiation and prescription at CHPY.  
The theory of diffusion of innovation by Everett Rogers originated in the field of 
communication to explain how an idea or product gains momentum and diffuses 
through a specific population or social system (Kaminski, 2011). The Awareness to 
Adherence Model (AAM) also focuses on change, positing that any shift in mindset is 
dependent on the following steps: awareness, agreement, adoption, and adherence (Freed, 
Pathman, Konrad, Freeman, & Clark, 1998). 
These two models, when applied to the AYA ComPrEP Project, represented 
various processes that aided in implementing this protocol. The awareness adherence 
model was useful in identifying ways to improve clinicians and staff members’ adherence to 
PrEP guidelines by demonstrating where clinicians and staff fell off the path to adherence, and 
when they were at greatest risk for not attaining each step in the clinical protocols. An initial 
gap assessment looked at factors associated with a greater likelihood of attaining the steps 
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toward guideline adherence. The adherence model was also used to describe how the AYA 
ComPrEP would increase awareness of PrEP clinical practice guidelines through education 
and training for clinicians. Training reviewed HIV-risk identification and the specifics of the 
HIV-risk screening protocol. Understanding the rationale and benefits of making robust PrEP 
services available to adolescents and young adults, clinicians and staff would more likely to 
follow the new HIV-risk screening protocol. Over time, the goal was that this program, 
AYA ComPrEP, would be disseminated among clinicians, staff members and its 
patients (adolescent and young adults) until a saturation point is reached, and the 
majority of staff and patients adopted the new practice as status quo.  
One of the goals of AYA ComPrEP was to provide effective, standardized services and 
then document what was most successful in this model so it could be scaled and applied in 
other communities, initially in the San Francisco Bay Area. The AYA ComPrEP would be a 
well-timed initiative if State of California funding is secured for PrEP provision. 
Specific Aims 
The overall goal of the AYA ComPrEP Project was to improve HIV prevention in 
adolescents and young adults (AYA) by preparing clinicians and/or clinic staff to confidently 
provide PrEP services to this populations (Appendix C). The interventions were designed to 
increase clinician and clinic staff identification of AYA with substantial HIV risk and create 
an education platform on PrEP targeting the needs of AYA. Specifically, it was projected 
that by April 2020, clinicians and clinic staff who participated in the training 
workshops would have increased knowledge and comfort to prescribe PrEP 
demonstrated by at least 80% of the clinicians with increased knowledge score in post-
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training and verbalization of comfort and readiness to provide PrEP and HIV 
preventions services to at-risk adolescents and young adults.  
Stakeholders 
Stakeholders for the AYA ComPrEP Project included the leadership, providers, staff, and 
patients of CHPY, their partner agencies including non-government organizations, and other 
clinicians and primary care providers and staff who maybe interested about PrEP services for 
AYA. The partner agency of Balboa Teen Clinic includes the Balboa High School of the San 
Francisco Unified School District (SFUSD), which the clinic is located. A complete list of 
CHPY clinics is shown in Appendix D. Through partnership and collaboration, CHPY is tasked 
to take the lead in providing HIV prevention services for AYA in San Francisco and contribute 
to the achievement of the SFDPH’s mission in the ‘Getting to Zero’ initiative. Other stakeholders 
are the public health and local health clinics, as well as public and private organizations working 
for the health of adolescents and young adults. Pharmaceutical companies, particularly Gilead 
(the maker of Truvada™ and Descovy™), may also be interested in this project, since they have 
a history of support for projects related to PrEP.  




Gap Analysis & Needs Assessment Results 
Upon consultation with CHPY leadership, the author received permission to conduct this 
project at CHPY (Appendix E). After the development of the project proposal, the author 
performed a gap analysis by observing clinical practice, reviewing existing clinical data on PrEP, 
and staff interviews. Within San Francisco, PrEP is currently offered in two clinics of CHPY: 1) 
Cole Street Clinic, and 2) Larkin Street Clinic. It is not offered at Balboa Teen Health Center 
where the project was implemented. Based on clinical observations at both Cole and Larkin, 
standardization for HIV prevention is lacking, particularly in the identification of at-risk PrEP 
candidates. Based on an initial review of the CHPY intake form in the electronic health record 
and staff interviews, it appears that there are currently no patient inquiries related to PrEP use or 
PrEP prescription during initial intake.  
While the STI screening template is available in the electronic health record (e.g. a series 
of screening questions asking for the number of sexual partners of patients, use of condoms, and 
STI symptoms), there is no standardized template that specifically prompts clinicians to analyze 
HIV risk and initiate PrEP counseling or intervention. To increase PrEP prescription, a standard 
assessment template is needed in the electronic record that CHPY clinicians use to do risk 
assessment and identify PrEP candidates. Sexual history and other risk behavior assessments are 
also being performed inconsistently. Currently, initiation and prescription of PrEP is merely 
based on the clinician’s individual judgment or preference, or whether the patient requests PrEP.  
There are times when clinicians feel so uncertain of the guidelines and policy they call other 
clinicians assigned at other clinics to consult on whether to prescribe PrEP. This is a time-
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consuming process that can be avoided if training for clinicians and staff is regularly done, and 
more standardized screening tools, templates, and protocol are implemented.  
While data on PrEP prescriptions at CHPY clinics was generated through the electronic 
health record and followed by the SFDPH PrEP monitoring group, the majority of clinic staff 
and providers at CHPY have not seen the specific research findings and data on PrEP reduction 
of HIV infection. There is also the need for clinic staff to understand the data and analyses of 
PrEP prescription at CHPY to track and improve its clinical practices on HIV prevention for 
AYA.  It is estimated by CHPY that of all its patients who are started on PrEP, around 30% of 
them discontinue taking PrEP without follow-up. Based on chart reviews of some CHPY 
patients, not all patients who tested for sexually transmitted infections such as gonorrhea and 
chlamydia are screened for PrEP, particularly heterosexual AYA patients. A significant gap 
exists between the number of at-risk patients who qualify for PrEP and the number of these 
patients who were actually offered PrEP. The initial gap assessment revealed lack of 
continuation of PrEP after implementation, lack of follow-up for those who discontinued PrEP, 
and in specific cases, conversion of adolescents to HIV positive.  
Upon consultations with CHPY Leadership and PrEP Champion, it was decided that 
rolling out PrEP at the 3rd biggest clinic of CHPY, The Balboa Teen Clinic, would be more 
beneficial for CHPY and the adolescents of San Francisco who may benefit from PrEP. A needs 
assessment through in-depth interviews was suggested and carried out. Tools such as the Project 
Information for In-Depth Interview Participant (Appendix F) and the In-Depth Interview 
Questionnaire (Appendix G) were developed for the needs assessment.  
According to the results of in-deep interviews (Appendix H) and gap analysis, it was 
determined that CHPY would benefit from the implementation of the AYA ComPrEP Project, 
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which focused on education or training of clinicians and staff on PrEP. In-deep interviews 
among nine staff of the Balboa Teen Center were conducted from December 12, 2019 to January 
30, 2020. The result of the in-depth interviews revealed the following themes or issues related to 
making PrEP services available in the clinic:  
1. All participants want to have PrEP services available at Balboa Teen Health Center. 
Everyone is excited about it. The thought that this will be the first school-based PrEP in 
California (one of the firsts in the United States and countries in the world) excites the 
team; 
2. Each team member has a role to take in this initiative. There is a need to clarify or 
communicate roles. Everyone is willing to participate;  
3. Staff members need education, training, and workshop both for first timer and as a 
refresher for those who had a PrEP training previously before seeing patients in the clinic 
for PrEP outreach, education/counseling and PrEP prescription; 
4. Clinic members voiced the need for materials on PrEP, including presentation materials 
about PrEP for AYA for teachers, staff, students, and patients.  
5. All interviewees pointed that the clinic need good outreach and dissemination strategies 
to reach communities and potential patients of PrEP services in Balboa. 
GAANT 
The AYA ComPrEP Project implementation took place from September 2019 to April 
2020 (Appendix I). Since 2018, the author had planned the project with DNP Chair, Dr. Prabjot 
Sandhu and DNP committee member Dr. Stefan Rowniak. Approval for the project with the 
CHPY leadership: Dr. Lori Kohler (Medical Director), Carol Tanuguchi, NP (Clinical Nurse 
Lead), and Adam Leonard, NP (PrEP Champion at CHPY) was given in September 2019. 
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Earlier, starting May 2018, the author initiated this project topic after researching the evidence-
based literature on barriers to PrEP in AYA. A brief gap analysis of CHPY’s PrEP 
implementation practice has been done followed by needs assessment. Conducting the needs 
assessment revalidated the gap analysis. February through November 2019 have been spent on 
the initial planning for AYA ComPrEP, which has included consultation with experts and staff, 
review of literature, and exploration of guidelines, screening tools and templates. The second 
milestone, in-depth interviews with Balboa Teen Health Center was completed on December to 
January 2020. PrEP manual and binder were created, and modules for training workshops on 
AYA and PrEP were developed from December to March 2020.  
Subsequently, in a third phase, the education piece, the training and workshop was 
conducted in April 2020. However, in light of COVID-19, with the closing of the Balboa Teen 
Health Center, an online simulation for clinicians (NP students) of the University of San 
Francisco. The scheduled training and workshop for Balboa clinicians and staff on March 13, 
2020 was cancelled due to the closure of the clinic related to the ‘shelter in place’ policy in 
placed as a measure against the COVID-19 pandemic. The fourth and final milestone, evaluation 
of the intervention and its measurable outcomes was completed by the end of April 2020. 
Dissemination of the results took place by May 2020 and onwards.  
Responsibility/communication plan. Planning for the AYA ComPrEP Project required 
interdisciplinary responsibility and continuous communication (see Appendix J for the work 
breakdown and Appendix K for the communication plan).  
The interprofessional collaboration for this project had occurred primarily among the 
author, Adam Leonard, NP, Carol Taniguchi, NP, and Dr. Lori Kohler of CHPY, and the 
author’s DNP committee advisers, Dr. Sandhu and Dr. Rowniak. Working directly with Carol 
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and Lori, the author was responsible for the development, implementation, management, and 
evaluation of the project. Carol and Lori lead the CHPY program, serving as clinical experts on 
CHPY’s patient population, and on HIV prevention. As CHPY’s lead director and nurse 
practitioner, they have provided authorization for the AYA ComPrEP project and potential 
changes to clinical practice on site. Adam Leonard, NP was CHPY’s Champion on PrEP having 
had experiences on PrEP prescribing and being the clinician who initiated PrEP services at Cole 
Street Clinic and Larkin Street Clinic. He met with the project author multiple times, provided 
gaps, information, guidance of the project within CHPY, and recommended Balboa Clinic as the 
implementing site. Dr. Sandhua and Dr. Rowniak provided feedback and guidance all throughout 
the planning, implementation, and evaluation phases of the project, including the approval of the 
online simulation training for clinicians of USF. 
SWOT Analysis 
The following SWOT analysis describes the project’s strengths, weaknesses, 
opportunities, and threats in relation to CHPY that have the potential to affect its implementation 
(Appendix L).  
Strengths. CHPY is the youth arm of the San Francisco Department of Public Health, 
serving adolescents and young adults. It is a smaller program in a bigger public health 
organization that has three team leaders, which makes managing the bureaucracy easier. CHPY 
is comprised of more than ten major and satellite specialty clinics across San Francisco. It 
provides comprehensive clinical services for adolescents and young adults (AYA) ages 12-25, 
including those who are transgender and homeless (SFHN, 2018). CHPY nurtures an 
environment that is compassionate and sensitive to its patients’ culture and beliefs. It provides 
primary care and reproductive health services to all AYA regardless of their socio-economic 
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status. Both the patient population and CHPY staff members share similar backgrounds as 
LGBTQ community members and/or people of color, producing a trusting environment that is 
open to change for improvement. The Family Planning program (FPACT) of the State of 
California reimburses CHPY clinics for family planning services, which could cover PrEP. 
CHPY also has an emergency fund for patients who have no insurance, which could additionally 
cover PrEP medication. This funding would address a vital need, given that CHPY’s patients 
represent an at-risk AYA population that qualifies for PrEP. Given the magnitude of this need, a 
DNP project focused on youth and young adults at risk of HIV infection is appropriate and 
relevant. The agency’s strengths support the project’s potential to improve PrEP clinical 
implementation for AYA patients. 
Weaknesses. CHPY has been through a great many changes in the past two years, 
including disruptive events such as staff resignation and transfers to other departments. CHPY 
recently lost two of its three nurses, who were well trained in screening for PrEP. Towards the 
last quarter of 2020, one of the clinicians of CHPY who started PrEP at Larkin and Cole clinics 
also resigned. Despite being a part of the wider SF Health network, some clinicians of CHPY are 
not clear of the protocol on PrEP specifically for AYA. There is also a need for clinicians to 
update about the specifics of the PrEP medications available and when to use them. The new 
EHR system represents another challenge, because of the new transition from eCW to Epic, it 
was expected that there would be limitation to capture clinical data. Difficulty navigating the 
former EHR (eCW) posed problems in this DNP project during the baseline assessment and 
evaluation. Therefore, project implementation could face difficulties with technology and 
adherence to change in practice.  
Opportunities. CHPY is part of the broader SFDPH, which could provide access to 
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funding and opportunities for additional support.  SFDPH is known for its competency in 
providing quality HIV prevention and management interventions, particularly to key populations. 
CHPY is also a part of the recent Getting to Zero initiative for San Francisco, focusing on young 
people. Currently, one-third of new HIV infections are among young people ages 12 to 24, 
making it strategic for CHPY to strengthen its PrEP program in order to be proactive in HIV 
prevention in San Francisco. The announcement of FDA approval for Truvada use as PrEP for 
young people below 18 years of age will make the medication more acceptable to clinicians. 
Threats. Obstacles to PrEP use include patient refusal of the medication due to lack of 
awareness of its effectiveness, negative attitudes toward PrEP, economics, lower adherence and 
retention rates, relationship status, and stigma. Taking PrEP medications entails financial burden, 
particularly for those who have no insurance or have no access to PrEP subsidy programs. In a 
study of AYMSM by Holloway et al (2017), young men of color often voiced concerns about the 
cost of PrEP. While some health insurance plans such as Medi-Cal cover the entire cost of PrEP, 
others do not. Adherence to PrEP is viewed by AYMSM as difficult in the long term. AYA were 
concerned about missing pills, developing resistance to PrEP, and contracting HIV (Perez-
Figueroa et al, 2015). Regardless of age or gender, about half of participants interviewed in one 
study were extremely worried about the negative side effects of PrEP (Fisher et al, 2017). 
Another of the barriers to PrEP uptake is cultural stigma, which stems from pre-existing 
attitudes toward HIV, and specifically depicts patients taking PrEP as “Truvada whores.” Yet the 
perception of low HIV-risk is the primary reasons AYA decline PrEP, representing an 
individual-level barrier to PrEP uptake. For these reasons an identified at-risk patient may refuse 
PrEP evaluation, and an eligible patient may refuse to initiate PrEP. Such threats could affect the 
PrEP implementation cascade, and subsequently, this project’s measurable outcomes. 
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Budget and Cost Benefit Analysis 
This project was implemented without financial cost to CHPY by utilizing available 
resources within SFDPH, its networks, and partner agencies. The author absorbed the majority of 
the project’s cost as an unpaid resource responsible for project development and management. 
Some cost of this project was taken from the Jonas Scholarship fund that was received by the 
author. The cost of implementing the project was $660 (Appendix M), which consists of 
materials developed and used for AYA ComPrEP folders and binders Going forward, for Balboa 
Teen Clinic, one staff member such as a nurse, medical assistant, or a person from the partner 
non-profit organization should function as a PrEP coordinator, comparable to a vaccine 
coordinator, such as a nurse or medical assistant. This work is already part of staff duties, and 
would simply be more clearly defined. Consequently, this role would not entail increased salary 
costs, so it is not included in the project budget.  
By preventing HIV infection, this DNP project produces a significant benefit of cost- 
avoidance and savings in HIV management (Appendix N). HIV antiretroviral treatment costs 
approximately $20,000 and upwards per patient per year (CDC, 2015). The cost of PrEP 
pharmacotherapy is $13,000 per patient per year. If all of CHPY’s suspected at-risk patients 
acquired HIV and required antiretroviral treatment, that would entail significant resources, 
minimally $20,000 annually per person. When patients are started on PrEP and HIV infection is 
prevented, an estimated $7,000 in costs per patient are avoided each year. By expanding PrEP 
implementation, this project also produces a return on investment (ROI) unique to CHPY in the 
form of increased health insurance reimbursements. CHPY qualifies for Medi-Cal and Family 
Planning reimbursement. It is important to clarify that initiating PrEP for established Medi-Cal 
patients does not create additional reimbursement. However, PrEP treatment does require 
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frequent follow-up, which would keep patients in care, contributing to patient retention, and thus 
reimbursement (Appendix I). Other than the financial benefits, there are benefits related to 
quality of life, decreased stigma, decreased suicide rates in this population, and increased access 
to prevention services for most-at-risk populations. HIV prevention strategies that include PrEP 
are beneficial for most at-risk populations than allowing them to get infected and then later have 
them on HIV disease management. 
Pre-Implementation Intervention 
Screening Tool Development. Prior to the implementation of the project, the 
development of screening tools was done. This initial phase of the project included the 
revision and adoption of existing STI screening tools of CHPY to include screening for risk of 
HIV infection. The screening tool was based on available risk assessments such as the Clinical 
Practice Guidelines of the CDC, guidelines from the WHO, the California Department of Public 
Health (CDPH), the SFDPH, and the PrEP Education for Youth-Serving Primary Care Providers 
Toolkit developed by the Sexuality Information and Education Council of the United States 
(SIECUS). They are available online but have to be reviewed and tailored to the needs of the 
AYA populations.  
• Performance of a gap analysis. An assessment was performed to determine what 
type of screening tools are currently used for PrEP, HIV, and STI assessments. 
• Selection of optimal screening tool. The most appropriate tool was selected after the 
need was clearly established. Tools that were used in this project included the Quick 
Clinical Guide: HIV PrEP developed by the AIDS Education & Training Center 
(Appendix O), and the Ask about PrEP (Appendix P) of the San Francisco 
Department of Public Health.  
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• Development of a screening tool, if necessary. The tools recommended by the 
CDC, the WHO, CDPH, SFFDPH, and SIECUS meet the needs of health care 
delivery to adolescents at Balboa Teen Clinic. The WHO tool was adopted for 
screening of risk (Appendix Q). 
• Establishing the screening protocol. A model screening protocol and algorithm for 
offering PrEP to patients was adopted and developed by reviewing current policy and 
clinical nursing algorithms, evidence-based practice, and the recommendations of 
PrEP experts, clinicians, and staff. The algorithm of the SFDPH was adopted. 
• Integrating risk assessment into existing STI screening. These inquiries could be 
integrated into the electronic health record (EHR) but was not done due to the 
limitation as a result of the COVID-19 pandemic. However, a one-page laminated 
Clinical PrEP essentials developed by SFDPH for providers is available for use 
(Appendix P). Relevant questions relate to sexual preference and practices, potential 
HIV exposure, and STI status is also developed.  
In a setting such as the Balboa Teen Clinic, as adolescent patients are roomed, clinic staff 
(nurses, medical assistants, and health workers) are expected to competently use the AYA 
ComPrEP screening tools to assess for HIV risk. This provides an opportunity to offer 
information to each new patient on sexually transmitted infections including HIV and AIDS, as 
well as STI testing, and prevention strategies including PrEP. Clinic staff should be able to 
identify at-risk AYA and communicate that risk to the clinician.  
Implementation 
The AYA ComPrEP was designed as a HIV-prevention program utilizing PrEP, developed 
for the San Francisco agency, Community Health Programs for Youth. The program integrated 
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the biomedical and AIDS risk-reduction models to optimize PrEP intake among adolescents and 
young adults. The project was implemented in three phases: 
1) Education of staff or clinicians 
2) The use of the screening tools and protocol integrated into the workflow or the EHR 
system 
3) Evaluation of the AYA ComPrEP Project 
Part 1. Clinicians and Clinic Staff Training and Seminar 
The education piece for clinicians was done online via Zoom conference. The author with 
the guidance of Dr. Sandhu created a training agenda (Appendix R) and four modules for the 
online training presentation.  
1.1 Providing vital updates on HIV and PrEP. Clinical content were drawn from 
public health information of the WHO, CDC, CDPH, SFDPH, and SIECUS.  
• Module 1 covered the basic of sexually transmitted infections and HIV & AIDS 
(Appendix S), while module 2 discussed about the key elements of HIV counseling 
(Appendix T).  
• Discussion included a series of relevant facts about adolescents motivating providers 
to provide youth-friendly services, which include a review and understanding the 
realities of young people, their reproductive health, and the SOGI initiative for 
module 3 (Appendix U).  
• FDA recommendations for PrEP, summaries on the safety of the newest PrEP drugs, 
which have reduced toxicity and therefore less risk to liver and kidney health, and 
alternate dosing protocol, which also reduce the amount of drug required and 
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therefore the level of toxicity and potential side effects were covered on Module 4: 
Pre-Exposure Prophylaxis Appendix V).  
1.2 Switching the focus of the training. Two separate training workshops were first 
suggested for the clinician and staff of Balboa Clinic but then later changed to be a joint-
seminar. The face-to-face seminar at Balboa Teen Clinic was scheduled but was 
cancelled due to the COVID-19 pandemic. As an alternate, an online simulation was 
done for clinician trainees of USF. This online seminar aimed to increase the comfort 
level and ease with which providers initiate and prescribe PrEP to AYA who are at high-
risk of HIV infection.  
1.3 Developing additional professional materials. In addition to the seminars, the 
author created information packets in a pocket folder, complete with index tabs, so 
clinicians can quickly access Q & A summaries from the literature on effectiveness rates, 
alternate dosing protocol, side effects, insurance, financial support, and other potential 
concerns. 
Part 2. Patient Education and Motivation. This intervention has not happened yet due to the 
closure of the school and clinic related to the COVID-19 pandemic. 
2.1 Supporting patient self-care. The decision to take PrEP may be attributed to 
patients’ recognition of their risks, making a commitment to reduce high-risk sexual 
contacts, and to increase low-risk activities. Those at high risk for HIV will be offered the 
option of enrolling in a PrEP program, and staying in contact with a health care 
environment where they have access to reproductive and sexual health services.  
2.2 Providing patients with the most current information.  
PrEP IN ADOLESCENTS AND YOUNG ADULTS 
 
41 
• Regarding permission to prescribe, many adolescent patients are unaware that 
they are now legally empowered to obtain PrEP with total confidentiality, and 
without their parent’s consent or knowledge.  
• Concern over toxicity is another reasonable objection raised by young patients, so 
relevant information will be included on the most recent form of PrEP with lower 
toxicity, as well as alternate dosing schedules that reduce the amount of the drug 
required. 
2.3 Engaging patients with age-appropriate materials. The author has observed how 
motivating the use of Quit Smoking kits have been in the CHPY clinics. Using this 
program as a model, ComPrEP kits will be designed especially with youth in mind. These 
are bags that contain freebies, condoms, and educational materials on PrEP and HIV 
prevention similar to the Quit Smoking Kits currently distributed by the San Francisco 
Department of Public Health.  
Part 4. PrEP Protocol Implementation and Evaluation 
Implementation of the HIV screening tools and PrEP protocol will be integrated into the 
electronic health records of CHPY and demonstrated in the seminars. Use of the screening tool 
and protocols can begin immediately, on completion of the training. Following the seminars, 
personnel will receive an assessment of the training, which will include open-ended questions on 
possible improvements. A follow-up assessment will also be performed 6-8 weeks after the 
training and seminars.  
Study of the Methods 
After launching the education piece of the AYA ComPrEP, which methods statistical, 
analytical, qualitative? Etc. for evaluating the effectiveness of the online training and workshop 
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and simulation to implement the use of PrEP guidelines and screening protocol were performed. 
In the arm of the intervention for clinicians, post-training competency a survey aimed at 
assessing increased knowledge were evaluated using baseline and post-test scores. Evaluation of 
clinicians’ comprehension and comfort to initiate dialogue and prescribe PrEP was performed 
through the post-training evaluation. Each participant was asked to submit a plan for changes in 
practice were asked at the end of the training. This data can be used to re-assess the impact of the 
project in the routine utilization of the HIV PrEP screening tool and the established screening 
process in their practice. 
Outcome Measures  
Primary outcomes. Initially, the primary intent of the project was that by the end of 
April 2020, the Balboa Teen Clinic will have integrated the AYA ComPrEP program into 
their practice, offering PrEP services to its patients looking at the percentages in 
knowledge increase, the use of guidelines, and satisfaction with the implementation of the 
new risk assessment and the PrEP protocol by clinicians and staff in their practice. However, 
due to closure of the school and the clinic, the primary outcomes were limited to conduct 
of the online training and workshop for the clinicians of the University of San Francisco. 
These outcomes can be used as a basis for recommendations for training and seminar on 
PrEP for AYA for other clinic and for Balboa Clinic when it opens in the future. The 
following modified primary outcomes were used to evaluate the effectiveness of AYA ComPrEP 
Project, based on improvement from baseline clinical practice and outcomes (Appendix G): 
• Clinicians at CHPY and the University of San Francisco are well recognized 
for their training, expertise, and willingness to learn. In this context , it is 
projected that as many as 80% of the clinicians who attended the training 
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workshop will have increased knowledge on HIV and PrEP demonstrated by 
achieving at least 80% passing rate on the training knowledge competency 
evaluation; 
• At least 80% of the clinicians who attend the training workshop will have 
increased in enabling or non-stigmatizing attitudes on HIV and PrEP; 
• At least 80% of the providers will use the guidelines (e.g. risk assessment tool and 
protocol) in practice demonstrated in the case studies simulation; and 
• At least 80% of the clinicians will state increased comfort in prescribing PrEP 
to AYA patients after the simulation. 
Analysis 
Quantitative and qualitative analytical methods were used for the evaluation of the AYA 
ComPrEP Project such as descriptive statistics that provide the demographics of clinicians and 
staff who participated in the intervention. Evaluation tools were developed to gather data for 
analysis of outcomes using the Likert Scale, a psychometric measure widely applied in survey 
research. Evaluation tools included pre- and post-training survey questionnaires consisting of 
knowledge and attitude statements, and structured and close-ended questions.  
Data Instruments and Measurement.  
The questionnaires (Appendix M) used for in-depth interviews and simulation training-
workshop consisted of structured mixed multiple choices, true or false, and close-ended 
questions. The development of the instruments was based on review of literature and inputs from 
the CHPY leadership, CHPY PrEP Champion, and the DNP committee of the investigator who 
have expertise on developing survey questionnaires for analysis. Instruments used were designed 
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specifically for this project. The participants of the in-depth interviews and pre-and post-
simulation surveys were encouraged to ask questions to clarify any instructions. Data from the 
in-depths interviews were used to identify gaps, challenges, and recommendations by Balboa 
Teen Clinic staff on PrEP program implementation (the author planned to write a separate 
manuscript on the results of the in-depth interviews). The results of the pre-and post-training 
workshop were used as the intended outcome of this project, which focused on education of the 
clinician trainees of USF (nurse practitioners). The pre- and post-simulation questionnaires asked 
for information about: 
Socio-demographic and Background Information. This short section asked about the 
DNP track, year of birth, gender, and sexual orientation of the clinician participants.  
HIV and PrEP Knowledge. This section was used to analyze the change in knowledge 
scores of clinicians after attending the training workshop in compared to the baseline.  The 22-
item true or false knowledge questionnaire asked mainly about HIV transmission, prevention, 
and the use of pre-exposure prophylaxis (PrEP). Each item was given equal weight in scoring. 
Correct answer were scored one point while incorrect response scored zero. The possible range 
of knowledge scores is 0-19. 
Enabling and Non-stigmatizing Attitudes. This section was used to analyze the change 
in enabling or non-stigmatizing attitude scores of providers before and after attending the 
training workshop. There were 22 statements included to measure the attitude scores. Positive 
statements were considered enabling or non-stigmatizing attitudes, the scores for responses were 
as follows: Strongly agree = 3; Agree = 2; Neither agree nor disagree = 1, Disagree = 0; Strongly 
disagree = 0. Others were negative statements and reverse scoring were applied to these items 
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when scores allotted. The higher the score, the better the enabling or non-stigmatizing attitudes 
of the providers. Attitude item score below 2 is considered stigmatizing attitudes. 
Data Analysis 
The author of this project collected and summarized the data using the SurveyMonkey 
and Excel spreadsheet. Descriptive analysis was done using the SurveyMonkey analysis built-in 
program. Likewise, some data were inputted on Excel. Microsoft Excel, a long-standing software 
program widely used in accounting, statistics, and the sciences, was used to analyze both the 
baseline and post-intervention clinical data that were not generated or run by the SurveyMonkey. 
Through SurveyMonkey and Excel, the results for each measure were calculated as percentages, 
from which graphs were generated. Graphs comparing baseline and post-intervention results 
revealed the effects of the educational training and seminars, and other interventions of the 
project. 
Ethical Considerations 
Ethical considerations directly involved in the AYA ComPrEP Project include patient 
privacy and potential conflicts of interest. Patient privacy was protected by strict adherence to 
the guidelines of the Health Insurance Portability and Accountability Act (HIPAA). While this is 
not a research project, per Institutional Review Board (IRB) guidelines, a waiver was filed. 
Capturing clinical data from the electronic health records were conducted onsite at CHPY clinics 
within a secure network. Patient names and personal information were excluded from the data 
captured and from the analysis of the intervention.  
Implications for the ethical practice of PrEP implementation in AYA in primary care are 
recognized by this project. In accordance with the American Nurses Association Ethical 
Standards and the Jesuit values of the University of San Francisco, the responsibilities of the 
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clinician and the healthcare site were examined. Providers must educate patients and weigh the 
risks versus benefits of taking PrEP to practice beneficence and non-maleficence. To practice 
justice, providers must also serve as diligent patient advocates by connecting disenfranchised, at-
risk AYA patients to social and medical services necessary to access PrEP. Despite well-
intentioned attempts, providers must acknowledge that their efforts to provide the best HIV 
prevention methods may still be blocked by forces outside of their control, such as patient 
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Section IV- Results 
PrEP Online Training Workshop and Simulation 
Nineteen clinicians (Nurse practitioner trainees or students) from the University of San 
Francisco participated in the PrEP online simulation training-workshop. Fifteen of the clinicians 
were first time to attend a training-workshop on PrEP and four of them have attended a PrEP-
related activity before (Figure 1) through the San Francisco City Clinic, the San Francisco 
Department of Public Health, and the California Association of Nurse Practitioner.  
 
Knowledge on HIV and PrEP 
Table 1 shows the differences in knowledge measured by the knowledge scores obtained 
from the pre-test training workshop and post-training workshop. There were 22 knowledge-based 













Figure 1. Have you attended a PrEP 
training or workshop before
Responses
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13 (59%) 16 (73%) 18 (82%) 16 (73%) 1.54 (7%) 
Post-Training 
Workshop 
15 (68%) 20 (91%) 21 (95%) 19 (86%) 1.76 (8%) 
Knowledge-based questions on HIV and PrEP answerable by True or False. 
Each question is marked as 1 point with total knowledge score = 22 
 
The overall results for HIV and PrEP knowledge in Figure 2 shows that clinicians had an 
increased in knowledge after the training workshop compared to the baseline. There is a 17.8% 
increase in overall mean knowledge score post-training workshop (mean KS = 19 or 86%) 
compared to that of the pre-training workshop (mean KS = 16 or 73%).  









Pre-Test | Mean Score 16 (73%)
Post-Test | Mean Score 19
(86%)
PrEP IN ADOLESCENTS AND YOUNG ADULTS 
 
49 
All clinicians had some knowledge on HIV and AIDS prevention prior to the online 
training-workshop and simulation. Table 2 shows that clinicians are aware that HIV infection is 
preventable (n=19). Likewise, all are aware that daily PrEP can prevent the sexual transmission 
of HIV by up to 90%, and that providing condoms is essential in HIV prevention and should be 
promoted even with PrEP.  
Table 2. Providers’ Pre and Post-Test Knowledge Score Difference on HIV Prevention & 
Condom Use 
Knowledge Items Correct Responses (%)  
Prevention of HIV Infection Pre-Test Post-Test 
There is a vaccine available to prevent HIV infection. (F) 18 (95) 17 (89) 
HIV infection is curable. A person infected with HIV can 
access cure at treatment clinics or hospitals. (F) 
17 (89) 18 (95) 
HIV is preventable. (T) 19 (100) 19 (100) 
Condom Use 
  
Using condoms can prevent HIV transmission and other 
STIs. (T) 
16 (84) 19 (100) 
The use of condoms should be promoted to prevent HIV 
infection. (T) 
19 (100) 19 (100) 
The use of condoms should not be promoted if a person is 
on PrEP. (F) 
19 (100) 19 (100) 
 
However, the pre- and post-training surveys reveals that clinicians have lack of 
knowledge about the effectiveness of PrEP to prevent HIV through vaginal sexual exposure and 
injecting drug use. About 64% of the clinicians (n=12) incorrectly believe that PrEP can reduce 
the risk of acquiring HIV among people who inject drugs by 30%, the same number of clinicians 
that incorrectly agreed that for PrEP to be effective against HIV infection through vaginal 
transmission, it should be taken continuously once daily for 7 days before engaging in 
vaginal sex. PrEP is 70% effective to prevent HIV transmission through injecting drug use while 
PrEP to offer protection through vaginal sex; PrEP should be taken for at least 21 days. 
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Table 3. Providers’ Pre and Post-Test Knowledge Score Difference on PrEP 
Knowledge Items Correct Responses (%)  
PrEP Pre-Test Post-Test 
For PrEP to be effective against HIV infection should be 
taken once daily and should be taken continuously for 7 
days before engaging in vaginal sex. (F) 
4 (21)  7 (37) 
Daily PrEP can reduce the risk of acquiring HIV among 
people who inject drugs by 30%. (F) 
4 (21)  7 (37) 
There is no alternative to daily dosing of PrEP. Other PrEP 
dosing is ineffective to prevent HIV transmission. (F)  
10 (53) 19 (100) 
Truvada is the only PrEP regimen available in the market 
to prevent HIV infection so it is easy to prescribe PrEP. (F) 
11 (58) 19 (100) 
Heterosexual men and women are not at risk for HIV 
infection and are not recommended for PrEP. (F) 
18 (95) 19 (100) 
Daily PrEP can prevent HIV transmission through sex for 
up to more than 90%. (T) 
19 (100) 19 (100) 
 
 
Also, another knowledge item that revealed poor understanding is the HIV transmission 
related to needle stick injury. This is similar to participant’s understanding of the evidence-based 
principle of U=U (Undetectable = Untransmittable), meaning people living with HIV with 
undetectable viral load are considered non-infectious based on clinical studies. They are unlikely 
to transfer HIV. This is a victory in the HIV response that clinicians should be highly aware of 
and should be used to empower communities of people living with HIV to take their HIV 
medications so not to transfer the virus to their sexual partners. Achieving and maintaining an 
undetectable HIV viral load is an evidence-based practice to prevent HIV transmission. 
 
Table 3. Providers’ Pre and Post-Test Knowledge Score Difference on HIV Prevention (Need 
Stick Injury and Undetectable = Untransmittable) 
 
Knowledge Items Correct Responses (%)  
HIV Transmission: Needle Prick Pre-Test Post-Test 
After needle prick injury with a needle from an HIV-infected 
patient, immediately gently expressing blood from the puncture 
site reduces the risk of contracting HIV infection. (T) 
9 (47) 11 (58) 
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After needle prick injury with a needle from an HIV-infected 
person, the chance of contracting HIV is less than 1%. (T) 
13 (68) 17 (89) 
After a needle prick injury with a needle from an HIV-infected 
person, a health worker may take HIV medications to reduce the 
chance of contracting HIV infection. (T) 
16 (84) 18 (95) 
HIV Transmission: Undetectable = Untransmittable 
  
A person with HIV who is undetectable is considered 
infectious. He/she is likely to transmit the virus to his/her 
partners through sexual intercourse. 
7 (37) 12 (63) 
A person will automatically get infected with HIV once he/she 
has sexual intercourse with a person living with HIV. (F) 
18 (95) 18 (95) 
 
 
Other knowledge items that were incorrectly answered by clinicians include the 
frequency of HIV testing for very high-risk patients. It should not be once a year per CDC and 
SFDPH but every 3 months guidelines. Likewise, children born to HIV-positive women does not 
equate to HIV-positive newborn or children.  
 
Table 4. Providers’ Pre and Post-Test Knowledge Score Difference on STI, Risk, and HIV 
Testing 
 
Knowledge Items Correct Responses (%)  
STI, Risk, and HIV Testing Pre-Test Post-Test 
A person who is at very high risk for HIV and other STIs 
should be tested once a year for HIV. (F) 
0 (0) 11 (58) 
One can be identified as HIV-positive by the way the 
person looks (e.g. signs and symptoms like skin ulcers, 
weight loss). (F) 
17 (89) 18 (95) 
If a person has a sexually transmitted infection (STI), 
his/her chance of getting HIV is higher. (T) 
18 (95) 19 (100) 
A person who has no sexual partner is not at risk for HIV. 
He/she should never be tested for HIV. (F) 
17 (89) 19 (100) 
Mother-to-Child HIV Transmission   
 
Children born to HIV-positive women are infected with 
HIV at birth. (F) 
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Enabling and Non-Stigmatizing Attitudes  
Table 5 provides the difference in enabling or non-stigmatizing attitudes of providers 
who participated in the online training-workshop. The mean enabling attitude score was 47 
(78%) for the pre-training and workshop survey while the mean enabling attitude score post 























31 (52%) 49 (82%) 55 (92%) 47 (78%) 6 (10%) 
Post-Training 
Workshop 
36 (60%) 55 (92%) 60 (100%) 53 (88%) 7.2 (12%) 
20 Statements on HIV and PrEP issues, Total EA score = 60  
Highly enabling response (strongly agree for positive statement or strongly disagree for negative 
statement) was marked for 3 points  
 
Enabling response (agree for positive statement or disagree for negative statement) was marked for 
2 points 
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Figure 2. Changes in Enabling or Non-Stigmatizing Attitudes, Pre & Post-Training 
 
 
Table 6 and 7 reveals the breakdown of items describing the providers’ enabling or non-
stigmatizing attitudes before and after the online training workshop. Prior to the training 
working, providers have stigmatizing (non-enabling) attitudes on 1) mandating disclosure to their 
partners of people living with HIV (mean attitude score 0.3, SD=0.58), 2) not allowing 
homosexuals to donate blood (mean attitude score 1.5, SD=1.31), 3) always involving parents for 
those on PrEP (mean attitude score 1.5, SD=1.31), and 4) believing they have the right to know 
the HIV status of patients in their practice including those that are not under their care mean 












Score | Mean Score
47 (78%)
Post-TW Attitude
Score | Mean Score
53 (88%)
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In my opinion, persons 
living with HIV deserve 










Homosexual men should 















People who are HIV 
positive should be 
encouraged to keep their 












A person who is HIV-
positive should be 
mandated to tell their 










 - 0.3 
(11%) 
0.58 
People who test positive 
for HIV should not 
engage in any sexual 
activity. 









Attitude Toward Person 
Living with HIV and the 
workplace 
       
I am uncomfortable 















A person who is HIV 
positive should not be 
allowed to work as a 
health worker. 







I have the right to know 
the HIV status of the 
patients/clients in our 
practice/unit/department, 
including those who are 














I am willing to work in the 
same unit/office with a 














Health care workers 
should be required for an 
HIV antibody test before 
engaging in any hospital 
or clinical practice. 









I have the right to know if 
someone in our workplace 
is HIV-positive. 






2.6 (86%) 0.61 
Attitude toward PrEP 
and role in HIV 
prevention 
       
As a professional health 
worker, I have the duty to 
educate the public on HIV 










Adolescents and young 
adults, including those 
below 18 years of age, 
who are at high-risk of 
HIV infection should be 





- - - 2.7 
(91%) 
0.45 
Counseling should be a 











assistants, health workers) 
should take an active role 
in adolescents PrEP 






- - - 2.9 
(96%) 
0.32 
Same-Day PrEP should be 
made available and 
offered to adolescents at-





- - - 2.7 
(93%) 
0.45 
It is embarrassing to talk 
about sex and condom use 
with patients, therefore, I 
should not initiate to talk 
about it with them 








Alternative PrEP dosing 
such as event-based 
dosing should be made 







- - 2.4  
(79%) 
0.68 
Condoms are for married - - - 2 17 2.9 0.32 
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people only. Adolescents 
should be prohibited from 
using condoms. 
(11%) (89%) (96%) 
Parents of adolescents, 
particularly those below 
18 years of age, who are 
on PrEP should always be 















Note: a Positive statements were considered enabling or non-stigmatizing attitudes, the scores for 
responses were as follows: Strongly agree = 3; Agree = 2; Neither agree nor disagree = 1, Disagree = 0; 
Strongly disagree = 0. 
 
Others were negative statements, reverse scoring were applied to these items when scores allotted. 
Attitude item score below 2 is considered stigmatizing attitudes. 
 
 
The result on Table 6 revealed that despite the model of online training versus in person 
training, there was an increase in enabling attitude scores, some providers remain to have 
stigmatizing or non-enabling attitudes on HIV issues such as mandating a person who is HIV 
positive to tell their partners about their HIV status, lowest attitude score of 1.3, SD=1.38. 
Likewise, attitude towards allowing homosexual to donate blood received the second lowest 
average attitude score, 2.1, SD=1.13. 
 
Table 6. Post-Training Workshop Attitude Scores by Attitude Items 
 

















In my opinion, persons living 
with HIV deserve their 
illness.  







Homosexual men should be 
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should be encouraged to 
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keep their diagnosis to 
themselves. 
A person who is HIV-
positive should be mandated 
to tell their partners about 














People who test positive for 
HIV should not engage in 
any sexual activity. 









Attitude Toward Person 
Living with HIV and the 
workplace 
       
I am uncomfortable 











A person who is HIV 
positive should not be 
allowed to work as a health 
worker. 







I have the right to know the 
HIV status of the 
patients/clients in our 
practice/unit/department, 
including those who are not 












I am willing to work in the 
same unit/office with a 






- - - 2.9 
(96%) 
0.32 
Health care workers should 
be required for an HIV 
antibody test before 
engaging in any hospital or 
clinical practice. 









I have the right to know if 
someone in our workplace is 
HIV-positive. 









Attitude toward PrEP and 
role in HIV prevention 
       
As a professional health 
worker, I have the duty to 
educate the public on HIV 





- - - 2.8 
(95%) 
0.42 
Adolescents and young 
adults, including those below 





- - - 2.8 
(93%) 
0.32 
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high-risk of HIV infection 
should be offered PrEP. a 
Counseling should be a part 





- - - 2.9 
(96%) 
0.32 
Non-clinician staff (nurses, 
medical assistants, health 
workers) should take an 
active role in adolescents 






- - - 2.9 
(96%) 
0.32 
Same-Day PrEP should be 
made available and offered 






- - - 2.8 
(93%) 
0.42 
It is embarrassing to talk 
about sex and condom use 
with patients, therefore, I 
should not initiate to talk 
about it with them 








Alternative PrEP dosing such 
as event-based dosing should 













Condoms are for married 
people only. Adolescents 
should be prohibited from 
using condoms. 







Parents of adolescents, 
particularly those below 18 
years of age, who are on 
PrEP should always be 














Note: a Positive statements were considered enabling or non-stigmatizing attitudes, the scores for responses 
were as follows: Strongly agree = 3; Agree = 2; Neither agree nor disagree = 1, Disagree = 0; Strongly 
disagree = 0. 
 
Others were negative statements, reverse scoring were applied to these items when scores allotted. 
Attitude item score below 2 is considered stigmatizing attitudes. 
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Training Workshop Evaluation  
Post-training, the participants’ feedback on the online training-workshop and simulation 
reveals that providers believed they achieved the objectives set for each module.  More than 88% 
agreed that they achieved almost all the objectives set for each module at the beginning of the 
training.  



































As a result of participating in the session 
"Module 1: The Basic of STI, HIV and AIDS," I 
am able to:
Responses
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Figure 4. Post-Training Workshop Evaluation Result on Module 2 
 






























As a result of participating in the session 
"Module 2: Key Elements for Ethical and 


















AYA client who may












As a result of participating in the session 
"Module 3: AYA and The SOGI Initiative," I 
am better able to:
Responses




Figure 6. Post-Training Workshop Evaluation Result on Module 4 
 



































As a result of participating in the session 
"Module 4: Pre-Exposure Prophylaxis for 
AYA," I am able to:
Responses













Presenter: Igor Mocorro, MPH, RN, PHN. 
This speaker's presentation skills were 
effective for the content presented.
Responses
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Participants Plan of Change 
 Providers were also asked to give at least three changes that they would do in their 
practice as a result of participating in the online training workshop (Table 7). 
Table 7. Providers’ Plan Change in Practice 
Provider 
Number 
Change in Practice Change Focus 
1 1) Being more comfortable with offering Prep. 
2) Being more open with discussing prep with patients. 
Use of PrEP Guidelines, 
Protocols, and Algorithms 
2 1) I feel more prepared to prescribe PrEP. 
2) I learned more about counseling prior to testing and 
will use that when discussing testing. 
3) I will open a bigger discussion into sexual activity 
Assessment and Risk 
Identification 
 
Use of PrEP Guidelines, 
Protocols, and Algorithms 
3 1) I will approach the young adolescent/adult population 
in a more sensitive fashion when doing a health and 
social history. 
2) I will able to consider some of the barriers to 
treatment and knowledge of this age population. 
3) I will know how to provide resources to their learning 
needs 
Prevention and Counseling 
 
Use of PrEP Guidelines, 
Protocols, and Algorithms 
4 1) Inquire about sexual history and practice as apart of 
primary care visits to Identify health risks 
2) Education on importance of safe sex practices  
3) Review the use of PrEP for those who are involved in 
high risk sexual behaviors 
Assessment and Risk 
Identification,  
 
Prevention Education and 
Counseling 
 
Use of PrEP Guidelines, 
Protocols, and Algorithms 
5 1) Understand and follow the PrEP guidelines. It is easy 
for me to understand it since we went over it in this 
simulation training date. I also did not know as NPs 
we could prescribe PrEP, I thought that only 
women’s health NP or other specialists could 
prescribe the medication.  
2) Be more mindful and aware of my nonverbal 
expressions 
3) Develop confidence to discuss PrEP and sexual 
histories 
Assessment and Risk 
Identification 
 
Prevention Education and 
Counseling 
6 1) Balance empathy with professionalism, not being 
overly reassuring 
2) Implement harm reduction tactics versus full 
Assessment and Risk 
Identification 
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prevention framework regarding high-risk behaviors 
3) Demonstrate confidence and confidentiality while 
taking a sexual history to promote trust and disclosure 
Prevention Education and 
Counseling 
7 1) I will feel more comfortable talking to this age group 
about sex. I will be able to initiate difficult 
conversations about sex. 
2) I will be able to adequately gather a health history 
that includes details about sexual health. I will use the 
information I gained about confidentiality for 
adolescents and young adults that use their parents' 
insurance to ensure that patients get the treatment 
they need and are able to maintain confidentiality. 
Assessment and Risk 
Identification 
 
Plan of Care and Evaluation 
8 1) Ask questions to open up dialogue about 
STI/HIV/AIDS in addition to safe sex & protection  
2) Reassurance & support about patient options and 
choices.  
3) Provide all pertinent info needed on STI/HIV/AIDS 
to make educated decision 
4) Be confident in using PEP & PrEP in clinical setting  
5) Report as mandated per CDC 
Assessment and Risk 
Identification 
 
Prevention Education and 
Counseling 
 
Use of PrEP Guidelines, 
Protocols, and Algorithms 
9 1) Prepare and have ready handouts related to physical 
anatomy and STIs and prevention 
2) Be aware of ways to help AYA access PrEP and PEP 
through community resources/LGBTQ support 
services 
3) Routinely screen AYA regarding sexual health and 
drug use. 
Assessment and Risk 
Identification 
 
Prevention Education and 
Counseling 
 
Plan of Care and Evaluation 
10 1) Initiate HIV/AIDS/STI discussion without fear 
2) Use CDC guidelines for management of STIs and to 
understand required reporting responsibilities 
3) Determine appropriate HIV/AIDS interventions by 
using the Primary Care HIV/AIDS algorithm and 
proper use of PEP and PrEP 
Assessment and Risk 
Identification 
 
Prevention Education and 
Counseling 
 
Use of PrEP Guidelines, 
Protocols, and Algorithms 
11 1) STD counseling 
2) HIV risk assessments 
3) PrEP prescribing and health monitoring. 
Assessment and Risk 
Identification 
 
Prevention Education and 
Counseling 
 
Use of PrEP Guidelines, 
Protocols, and Algorithms 
12 
 
1) Parents involvement not necessary to protect patients 
confidentiality for minors 
2) Be more open in sex education teaching 
Assessment and Risk 
Identification 
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3) Identifying their concerns and addressing them 
regarding sexuality 
Prevention Education and 
Counseling 
13 1) I don't work with AYA very much but I will certainly 
remember this material for when/if I am working with 
this population and will apply it to my adult practice. 
2) It is so important to always talk about sexual health 
with AYA but also with the adult and elderly 
populations. 
Prevention and Counseling 
14 1) Thorough questioning of sexual practices and 
preferences 
2) Addressing questions and lack of knowledge early 
3) Encouraging patient confidence by providing 
resources 
Assessment and Risk 
Identification 
 
Prevention Education and 
Counseling 
 
Plan of Care and Evaluation 
15 1) Learn to identify premature or unsafe sexual 
expression. 
2) Gained confidence in furnishing PrEP to this 
population. 
3) Learned how to educate this population on PrEP. 
Assessment and Risk 
Identification 
 
Prevention Education and 
Counseling 
16 1) Assessing the physical, mental, and social 
determinants of health for AYA 
2) Offering PEP and PrEP, and connecting them with a 
PrEP navigator to assist with financial and housing 
assistance 
3) Encouraging safe sex practices- prevention, 
screening, prophylaxis 
Assessment and Risk 
Identification 
 
Prevention and Counseling 
 
Use of PrEP Guidelines, 
Protocols, and Algorithms 
17 1) More information gained, therefore, more 
information shared 
2) Introduce AYA about the availability of PrEP and 
PEP in preventing HIV 
3) Help prevention of spread of HIV among all 
population actually not just AYA. 
Assessment and Risk 
Identification 
 
Prevention Education and 
Counseling 
18 In primary, I would  
1) Advocate for youth health 
2) STD screening for LGBT youth  
3) Educate about PrEP 
Assessment and Risk 
Identification 
 
Prevention Education and 
Counseling 
19 1) Asking about sexual encounters.  
2) Offer PrEP 
3) Offer more PrEP counseling. 
Assessment and Risk 
Identification 
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Section V. Discussion 
Summary 
The purpose of the AYA ComPrEP Project is to standardize PrEP screening tools, 
guidelines, and protocols to increase PrEP services provision for adolescents and young adults. 
In particular, the project aimed at integrating PrEP into the practice of Balboa Teen Health 
Center. However, due to closure of the school and the clinic, the primary outcomes were 
limited to conduct of the online training and workshop for the clinicians of the University 
of San Francisco. The goals of the online training workshops were achieved. Clinicians of 
the University of San Francisco who participated in the online training workshop had 
increased knowledge on HIV and PrEP (mean post training knowledge score of 86%). At 
least 80% of the clinicians who attended the training workshop have had increased in 
enabling or non-stigmatizing attitudes on HIV and PrEP (mean post training attitude 
score of 88%). Also, during the simulation, 100% of the providers used the guidelines (e.g. 
risk assessment tool and protocol) in case studies provided to them, demonstrating their ability to 
decide the plan of care of patients who need PrEP.  Likewise, 100% (n=19) of the clinicians 
have stated increased comfort in prescribing PrEP to AYA patients after the simulation. 
At CHPY, fortunately, the leadership is interested to having this project 
implemented and there is an on-going support for the author to train providers and clinic 
staff to provide PrEP services and integrate the PrEP protocol at Balboa Teen Health 
Center. While PrEP is currently a part of the services offered by CHPY clinics, there is 
the need to solidify protocols and procedures and to roll out PrEP services at Balboa Teen 
Health Center. Although it is intended that the project will effectively increase PrEP offering 
and prescription to patients of Balboa Teen Health Center, there were some setbacks or delays. 
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The author at the start anticipated possible challenges related to the implementation of 
the project such as push back from some clinic staff, particularly medical assistants who 
maybe not interested in doing interventions beyond drawing labs and providing  
counseling. This however was not evident for Balboa Teen Health Center based on the 
results of the in-depth interviews. Staff were supportive to bring PrEP services in the 
clinic although the results of the roll out of the actual PrEP services is yet to be seen. The 
shelter-in-place policy for San Francisco due to COVID-19 pandemic has delayed the 
actual implementation of the PrEP services at Balboa Teen Health Center. If it will push 
through, the author anticipates that the time required to effectively screen AYA for PrEP 
services may be seen as a barrier, reducing time from other clinic activities. In that 
context, it could be perceived as an added burden impeding clinic flow.  
Another challenge that the project may face is the transition to a new electronic 
health record for the entire SFDPH. The eCW software is now replaced by EPIC 
software. The author planned to be in consultation with the SFDPH IT team, which 
manages the software and electronic medical system of SFDPH to ensure that the 
screening tools or templates will be fully integrated into EPIC. However, based on the 
consultation, this maybe easy said than done. It was suggested though that the template 
for risk assessment or screening could be written on a Microsoft Word and then copied 
pasted to EHR if a built-in template is not possible to create right away. It is important 
that all clinic team members realize the value of the project and that everyone takes 
ownership. The continuation and sustainability of the project would be most successful if 
it is experienced not as a burden or extra work, but as an integral piece of the services 
CHPY provides for key populations most affected by HIV. The community clinics of 
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CHPY were developed specifically to mitigate the impact of the epidemics and health 
disparities on young people. 
Interpretation 
This project expected to improve the knowledge, enabling attitudes, and confidence of 
providers to provide PrEP services to adolescents and young adults. Results from the in-depth 
interviews of Balboa Teen Health center providers and staff show showed a great interest and 
enthusiasm to make PrEP services available in the clinic. The results from the interviews 
indicated the need for improvement in the clinic workflow and determination of roles and 
responsibilities in the roll out of PrEP services for AYA such as improving communication 
among staff, understanding the role of the PrEP navigator and staff from the San Francisco 
Unified School District (SFUSD) who are part of the Balboa Team Health Center team.  
The training workshop, which was modified to implement online and to target USF NP 
students, showed the lack of knowledge on PrEP for some providers such as knowledge on 
PrEP protection for vaginal sex, protection for people who inject drugs, HIV transmission 
by needle stick injury, and the frequency of testing for most-at-risk patients. Likewise, 
despite of the training workshop, some providers still showed stigmatizing or non-
enabling attitudes on the areas of blood donation from homosexuals, and mandated 
disclosure for those who have HIV-positive status to their partners.  
Limitations 
The AYA ComPrEP had some limitations; some of the interventions were not implemented 
or were modified due to the ‘shelter-in-place’ policy in the San Francisco Bay Area related to the 
COVID-19 pandemic. The PrEP training workshop for providers and staff of Balboa Teen Clinic 
scheduled on March 13, 2020 was canceled due to the school and clinic closure. While it was agreed 
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between the author and the clinic management to continue the training intervention for staff of 
Balboa Clinic, the date is unknown and it would not happen until the resume of classes at Balboa 
High School and the re-opening of the health center. While the training workshop piece was 
modified to involve nurse practitioner students of USF through an online training workshop and 
simulation, the project only measured the increase in knowledge, enabling attitudes, and 
confidence of clinicians post-training.  
The participants were asked to identify three changes that they plan to implement 
in their practice. This plan may not necessarily lead to actual change in practice. 
Providers who completed the online training workshop are unable to immediately offer 
PrEP services and depending on the type of their work, not  everyone may necessarily be 
prescribing PrEP. Since time from the training to the actual provision of PrEP services 
may take longer for the participants, their confidence may regress and additional follow-
up PrEP training maybe needed. Despite of the above-mentioned limitations, practice 
tools for offering services and prescribing PrEP were provided to the participants so that 
providers have resources to use if they need them. Likewise, they were connected to 
Lyric (non-profit organization that provides PrEP navigation support and other services 
for young people) and the PrEP navigator who expressed his support for continuous 
networking and collaboration. 
In terms of the training workshop, though the online training workshop for USF 
nurse practitioner students was a success based on the feedback on how it was done and 
the achievement of the objectives by the participants for each module, doing it online 
revealed some limitations such as the time allocated for online simulation. Follow-up 
discussions related to the results of the surveys were not done. If follow-up is possible, 
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this can create space for continuous discussions, identify emerging issues, and improve 
practices. There is a need for more time to discuss further the cases, questions, and 
concerns about PrEP for the adolescents and young adults.  
While the project measured the increased in knowledge and enabling or non-
stigmatizing attitudes of the providers who participated in the online training workshop, 
no statistical inference can be done between variables. We cannot associate the change in 
attitudes with knowledge scores. Likewise, scoring the enabling attitudes brought 
challenging ethical issues. While they are based on human rights approaches, 
interpretation can varies by situations, state laws. For example, the human rights based 
approach uphold confidentiality of HIV test result and a patient who is diagnosed of HIV 
should not be forced to disclose their status to their partners, there maybe an ethical 
dilemma for some providers on how to deal with such situation. Findings cannot be 
generalized to all the nurse practitioner students in the San Francisco Bay Area or in California 
in general because neither a random sample was used nor was the sample reflective of the entire 
population. However, the results showed interesting findings and support theories that the 
conduct of training workshops on any health topics improve knowledge and attitudes. . 
Conclusion 
The Community Health Program for Youth (CHPY) of the San Francisco Department of 
Public Health has the mission to keep adolescents and young adults in San Francisco healthy. 
Focusing on PrEP and other protective measures provides an opportunity for San Francisco to 
take leadership in HIV prevention. Given the complexity of adolescents and young adults, 
without comprehensive interventions, we could slip back into epidemic status. PrEP access by 
AYA is possible by breaking the barriers to PrEP prescription through education and training of 
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providers and clinic staff. This project demonstrated the needs for providers and clinic staff to go 
through PrEP education and training workshop to be able to provide quality PrEP services to 
AYA. Nurse practitioner students of the University of San Francisco who participated in the 
online training workshop were interested to learn and achieve competency in providing PrEP 
services and prescription to AYA. Training on PrEP for AYA (not only for adults) in primary 
care setting should be provided to all NP students across the nation. They need more discussions 
about issues of blood donations by key populations, HIV disclosure, and prevention of needle 
stick injuries. Stigmatizing attitudes should be addressed in PrEP and HIV education and training 
clinicians. Evidence-based research such as U=U (undetectable viral load = untransmittable 
HIV) should be discussed to eliminate stigmatizing attitudes and promote enabling environment 
for our most-at-risk populations. At times of COVID-19 pandemic, online simulation training 
workshop on PrEP was an effective alternative means if face-to-face training is not possible.  
The American Nurses Association (ANA) provides guidance on HIV and AIDS Nursing 
Scope of Practice and also addresses these infections in the more general Standards Scope for 
Nurses. Promoting effective HIV prevention with PrEP and empowering adolescents to reduce 
the risk of HIV transmission is within the nursing scope of practice, which includes assessing 
patient risk, creating plans for adherence, continuity of treatment, and evaluating patient 
response. While primary care clinicians, including nurse practitioners, physicians and physician 
assistants, play an important role in prescribing PrEP, registered and vocational nurses, health 
workers, and medical assistants have the capabilities needed to close the gap between the 
prescriber and the patient through PrEP education and counseling, conducting PrEP follow-up, 
and adherence support.  
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PrEP is a vital component of a robust HIV-prevention program in high-risk communities. 
This medication has proven to be safe and effective and is easy to prescribe and monitor. 
Currently, it is the only effective pharmaceutical interventions available to prevent HIV 
infections in key populations who engage in high-risk behaviors. PrEP can be prescribed by 
primary care clinicians, including advanced practice nurses and should be made accessible to 
AYA patients at risk of HIV infection, regardless of their socio-economic status or other 
background factors. If PrEP becomes widely accessible, including to high-risk adolescents and 
young adults, new HIV infections and the burden of lifelong HIV infection will be averted. Key 
populations such as young men who have sex with men will live healthier lives free from HIV 
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Section VIII. Appendices 
 
Appendix A. Types of PrEP Dosing 
 
Types of PrEP Dosing Dosing Description Number of tablets per 
week 
 
Daily PrEP TDF/FTC taken the same time daily. 7 tabs 
 






On-demand PrEP TDF/FTC before and after sexual 
activity: taking a loading dose of two 
tablets of TDF-FTC or placebo with food 
2 to 24 hours before sex. A third pill 
followed this dosage 24 hours after the 
first drug intake and a fourth pill 24 




Event-Driven PrEP Similar to on-demand PrEP; take 1 tablet 
before and after sex a total of 2 tablets 
and not 4 tablets as compared to the on-




Time-Driven PrEP Taking 1 tablet of TDF/FTC (Truvada) 
twice weekly with a post-sex dose, which 
59 participants were given in the study of 
Grant et al (2018) 
 
 
2 tabs + 1 tab after sex 
Intermittent PrEP Taking a pill of TDF/FTC on Monday 
and Friday, and 1 pill within 2 hours after 
sex, not to exceed 1 dose per day (Mutua 
et al, 2012). 
 
2 tabs + 1 tab after sex 
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Appendix B. Evidence Tables  
 
Table 1. Provider-Associated Barriers in AYA PrEP Use 
Question: What are clinician-perceived barriers to AYA PrEP use? 
Author Type of Evidence and 
Statistical Tools Utilized 
Study Findings Limitations 
1) Hart-Cooper 


















Cross-sectional online survey 
Descriptive analyses used to 
examine independent variables and 
outcomes (willingness to prescribe 
PrEP): 
• Means and SD (continuous 
variables) 
• Frequencies or Percentages 
(categorical and ordinal 
variables) 
Inferential statistics used using 
Stata IC 13.2: 
• Univariate and multivariate 
binary logistic models – to 
predict willingness to prescribe 
PrEP 
Nearly all providers had heard of PrEP (93.2%) and 
a third (35.2%) had prescribed PrEP. 
 
Almost all providers agreed that PrEP prevents HIV 
but fewer were willing to prescribe PrEP to young 
adults (77.8%) or adolescents (64.8%) 
 
Willingness to prescribe PrEP strongly associated 
with belief that: 
1) Providers had enough knowledge to safely 
provide PrEP to adolescents (OR 2.11, CI:  
1.18-3.76, p≤.01 and young adults (OR 5.19, 
CI: 2.15-12.50m P.001) 
2) Adolescents would be adherent (OR 3, CI: 
1.30-6.90, p=0.01) 
Low response rate 
and therefore 





therefore might be 
more willing to 
prescribe PrEP 
compared to most 
adolescents’ 
providers 
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(Internet-based Survey through 
SurveyMonkey) 
Descriptive analyses used to 
examine independent variables and 
outcomes (clinicians’ PrEP 
prescription intention and actual 
PrEP prescribing) 
Statistical analyses: 
*Sign test for paired data used to 
compare intention to prescribe to 
adults versus adolescents 
*McNemar’s test used to compare 
actual prescription of PrEP to 
adults versus adolescents 
*Univariate and multivariate 
logistic regression models were 
used to examine independent 
variables associated with intention 
and actual prescription of PrEP 
Clinicians had greater intention to prescribe PrEP to 
adults compared with adolescents 
Decreasing perceived provider-level barriers and 
barriers related to PrEP use in patients younger than 
18 was associated with improving access to PrEP for 
adolescents 
Cost of insurance was associated with decreased 
intention of PrEP prescription to youth 
More experience in non-occupational post-exposure 
prophylaxis (nPEP) was associated with actual 
prescription of PrEP 
Perceiving that multi-disciplinary teams and 
behavioral interventions are not necessary for PrEP 
delivery were associated with prescription intention 
and actual PrEP prescription 
Small sample size 
but high response 
rate; findings 
provided the basis 
for pilot data 
Recruitment of 
participants through 
a single research 
network 




risk categories (e.g. 
clinicians may not 
have had many 
homosexual or 









Qualitative Mixed-methods Study 
(Face-to-face and semi-structured 
phone interviews, open-ended 
questions) 
Clinicians’ perception of patient-level barriers:  
1) General lack of awareness of PrEP among AYA 
patients, especially those who might benefit from 
taking it 
2) Lack of clarity among AYA on policies about 
PrEP, parental permission, and confidentiality; 
Participating 
clinicians may not 
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October 2, 2012 




Data analyses using five-step 
framework analysis approach 
(familiarization, identification of 
thematic frameworks, indexing, 
charting, mapping, or 
interpretation) and employing 
NVivo (version 10) 
Data analyses of barriers 
categorized in four levels: patients, 
providers, organizations or systems, 
and community-level. 
patients were unaware that PrEP is classified as 
protected confidential care for adolescents 
Provider-level barriers include:  
1) Concerns about PrEP adherence by patients, and 
PrEP monitoring visits, including viral resistance 
development due to incomplete adherence 
2) Concerns about risk compensation; for example, 
the concern that patients might participate in riskier 
behaviors such as unprotected sex because they felt 
protected from HIV infection  
Concerns of prescribing to youth under 18: 
1) Maintaining confidentiality  
2) PrEP as a controversial therapy and possible 
negative publicity when prescribing PrEP in a 
pediatric practice  
3) Side effects and toxicity (e.g. negative effects of 
PrEP on bone density, accrual in cells and tissues, 
and renal function) 
Organizational and system-level barriers:  
1) High cost of PrEP, inadequate or lack of medical 
insurance  
2) Negative attitudes of colleagues 
3) Systems limitations 
4) Lack of resources including clinic space, 
providers’ time, and adequate support staff 
5) Access in the community: for example, 
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unwillingness to fill PrEP prescriptions by pharmacy 
staff  
6) Lack of awareness of PrEP among primary care 
providers 
Community-level barriers identified include stigma 
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October 2, 2012 






(Qualitative Interview followed by 
a Survey) 
Data analyses using five-step 
framework analysis approach 
(familiarization, identification of 
thematic frameworks, indexing, 
charting, mapping or interpretation) 
and employing NVivo (version 10) 
Clinicians were somewhat or very familiar with the 
guidance on prescribing PrEP in heterosexual adults 
(9/15), and adult MSM (13/15) 
Clinicians described characteristics of people who 
would and would not be appropriate for PrEP, 
including:  
1) presence of mental health illnesses or diagnoses, 
and/or 2) substance abuse issues. These are 
indicators of a person engaging in higher risk sexual 
behavior, with issues that could also negatively 
impact adherence to PrEP.  
Use of PrEP thought to be appropriate for 
serodiscordant couples attempting pregnancy 
There were concerns about the period of potential 
infection during PrEP initiation 
Most clinicians reported that behavioral 
interventions such as counseling on sexual practices 
should be a necessary part of PrEP interventions. 
Suggestions for PrEP delivery included: 1) condom 
use and safer sexual behaviors; 2) education on PrEP 
risks and benefit, adherence to PrEP, 3) substance 
Recruitment of 
participants through 










practices were based 




included those with 
experience 
prescribing PrEP. 
Clinicians who had 
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use avoidance, and 4) building or developing self-
esteem 
 
not prescribed PrEP 









Table 2. Patient-Associated Barriers in AYA PrEP Use 
Question: What are AYA perceived barriers to PrEP use? 
Author Type of Evidence and 
Statistical Tools Utilized 












100 included in 







October 2, 2012 
and April 23, 
Non-experimental 
Qualitative Interview followed by a 
Survey 
A semi-structured interview, 
included open-ended questions 
Participants recruited from the P18 
study (parent study) 
Data interviews transcribed, coded, 
and analyzed using NVivo 10 
(Welsh, 2002) 
Three primary concepts: 
1) Awareness of PrEP:  
• 50% were aware of PrEP 
• Some compared PrEP to birth control.  
• Despite awareness, participants (i.e. potential 
patients) expressed hesitation about PrEP use. 
• The majority expressed a desire for more 
information about PrEP. Questions include side 
effects, types of medications, active ingredients, 
odds of contracting HIV, and whether 
medication causes HIV.  
2) Attitudes toward PrEP 
• PrEP is one of several strategies. another source 
of protection other than condoms 
• Condoms would be easier to remember than 
taking daily medication  
• Consistent condom use equally effective, if not 
more effective, than PrEP. 
• Adherence could be difficult in the long term. 
Concern about missing pills and getting HIV, 
developing immunity to PrEP, and side effects.  
Not all the YMSM 
in the sample were at 
high risk for HIV. 
At the time of the 
interview, 
participants were 
enrolled in the parent 
cohort study for two 
years; these young 
men may have a 
better understanding 
of HIV prevention, 














• Cost of PrEP often voiced by YMSM of color.  
3) Social behavioral influences: 
• PrEP would provide a means of avoiding 
successful condom negotiation 
• Use of PrEP could justify not using condoms 
• The desire to engage in sex without a condom as 
a motivator for the adoption of PrEP. 
• The stigma of PrEP: a prevention strategy for 
those who engage in high-risk sexual behaviors 
or more frequent casual encounters 
• Relationship status: PrEP being seen as a trust 
and fidelity issue, taking PrEP could mean likely 
to have sex outside the main relationship. 
PrEP is protective if the partner is having sex 
outside of the relationship.  
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Sample Size: 
150 sample size, 
Non-experimental 
Qualitative surveys  
Descriptive analyses using 
frequencies, means, SD, and 
proportions were used for all survey 
responses. 
Chi-square and multivariate 
analyses of variance were 
performed to compare responses 
across gender identity and age 
Assessed the relationship between 
likelihood of PrEP adherence with 
• Half of the respondents said they would 
participate in a PrEP adherence study 
• Likelihood of PrEP adherence study 
participation significantly increased with the 
number of sexual partners, prior HIV or STI 
testing, prescription of HRT, the comfort of 
youth asking their MD about HIV prevention. 
• Interest in participation significantly decreased 
when the risk of HIV lessened. 
Regardless of age and gender identity: 
• About half of the participants were extremely or 
somewhat worried about the negative side 
The study was 
conducted 
anonymously, which 
may have affected 





The study may not 
have included youth 
from family-
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from a national 
online survey of 
transgender 
youth; 90 TM 
and 60 TF, 45% 




demographics, family disclosure 
and acceptance, and attitudes 
toward health benefits and risks of 
experimental procedures  
Multivariate regression used to 
examine independent effects 
 
effects of PrEP 
• One-third of participants did not want to 
additional medication to their health regime 





who may engage in 
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Sample Size: 78 
participants were 









Participants were recruited through 
the clinical sites affiliated with 
ATN in person and online 
Demographic and risk 
characteristics of the study 
population were examined using 
descriptive analyses  
All analyses conducted using SAS, 
version 9.4.  
Fisher Exact Test used to examine 
bivariable relationships between 
study outcomes and categorical 
characteristics  
Wilcoxon rank sum test used to 
examine bivariable relationships 
between study outcomes and 
continuous characteristics 
The first study on the safety and implementation of 
PrEP among adolescents MSM 
• Detectable TFV-DP drugs level in most 
participants throughout the study, 95% in first 12 
weeks but declining levels of drugs thereafter 
• No statistically significant associations between 
sex without condom use or receptive anal 
intercourse without condom use with last partner 
and TFV-DP levels over time 
• In comparison with respondents with protective 
levels of TFV-DP, those without protective 
levels were more likely to endorse the statement, 
“I worry others will see me taking pills and think 
I am HIV-positive.” 
• Most common reasons for missing doses of PrEP 
were: 1) being away from home; 2) being too 
busy; 3) forgetting; 4) changes in routine 
• There was a decreased in acceptability of pill 
size and taste from 12 weeks to 48 weeks among 
Generalizability of 
the findings maybe 
limited due to small 
sample size and lack 
of participation from 
some ATN sites  
Pharyngeal swab 
testing and samples 
were not collected. 
Urine and rectal 
swabs were only 
obtained at 24 and 
48 weeks. May have 
underestimated rates 
of STIs in the 
sample 
Time and resources 
needed to conduct 
this study were 
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McNemar test used when 
comparing binary measures 
between time points among 
participants 
 
study population substantial, may 
limit the ability to 
replicate findings in 
future clinical trials 
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Sample Size: 










Demographic and risk 
characteristics of the study 
population were examined using 
descriptive analyses  
Spearman correlation used to assess 
between pharmacologic (hair and 
DBS) and non-pharmacologic (self-
report and Wisepill) measures 
Adherence to PrEP waned over time among youth, 
particularly after week 12. 
Self-report of YMSM about using PrEP 
overestimates their actual adherence  
 
Wisepill devices 
were to provided to 
all study participants 
Reasons for Wisepill 
non-openings (e.g., 
pocketed doses) 
were not collected  
Participating YMSM 
were not asked their 
likelihood to use 
Wisepill in the future 
Recall of pill-taking 
over preceding 30 
days were measured 
based on self-report 




Anonymous survey data analysis 
 
Demographic and risk 
characteristics of the study 
Willingness to take PrEP was significantly 
associated with: 
1) Time since last HIV test  
2) Level of concern about becoming infected with 
Convenience 
sampling and the use 
of willingness as a 
primary outcome 








included in the 
analyses 
18-29 assigned 
male at birth, 
sexually active 
with other men 








online from July 
9 to August 20, 
2015 
population were examined using 
descriptive analyses  
Multivariate regression 
HIV 
3) Recent receptive condomless anal sex 
4) Use of illicit drugs in the past six months 
5) HIV risk index score 
YMSM unwilling to take PrEP had more concerns 
about stigma, drug effects, risk compensation, 
necessity, medical mistrust, adherence, and 
access/affordability. 
Hispanic/Latino patients more likely than white to 
take PrEP 
YMSM with medium and high concern for getting 
HIV were nearly twice as likely to be willing to take 
PrEP compared to YMSM reporting a low concern 
Increased medical mistrust associated with 
decreased willingness to take PrEP 
Greater concern about adherence associated with 
lower willingness of PrEP intake. Higher scores on 
perceived benefits associated with higher likelihood 
of desire to take PrEP. 
measure 
 
Participants were a 
self-selected group, 
may represent a bias 
towards those who 




may mean over or 
under reporting of 
willingness to take 
PrEP 
 
The study may have 
missed essential 
issues for YMSM 
that influence 
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Appendix C. Statement of Non-Research Determination Form 
 
DNP Statement of Non-Research Determination Form 
Student Name: IGOR G. MOCORRO, MPH, BSN, RN, PHN 
 
 
Title of Project:  Adolescents and Young Adults Comprehensive PrEP Education Project 
(AYA ComPrEP) 
 
Brief Description of Project:  
A) Aim Statement:  
Goal: To improve HIV prevention in adolescents and young adults (AYA) by 
preparing clinicians and/or clinic staff to confidently provide PrEP services to this 
population  
 
Aim: By April 2020, clinicians who participated in the training workshops will 
demonstrate increased knowledge and comfort to provide HIV prevention education 
services via a post training evaluation, and at least 80% will be ready to prescribe 
PrEP to at-risk AYA as demonstrated by actual prescriptions.  
B) Description of Intervention:  
Interventions of the AYA ComPrEP will include the creation of a 
comprehensive PrEP educational program with emphasis on PrEP and condom use 
initiation and prescription and condom use. An analysis of what constitutes an 
effective HIV and STI prevention program acceptable to AYA in the San Francisco 
Bay Area has been done in the previous year. The project interventions be divided in 
four major phases:  
• Screening Tools Development 
1.1 Develop by January 2020 the risk assessment and screening tool for clinical staff to 
improve identification of AYA patients at substantial risk for HIV and increase 
provider offer of PrEP at CHPY clinics. This can be done by revising the existing STI 
screening tools of CHPY to include screening on risk of HIV infection based on available 
risk assessments such as the Clinical Practice Guideline of the CDC, and the PrEP Education 
for Youth-Serving Primary Care Providers Toolkit developed by the Sexuality Information 
and Education Council of the United States (SIECUS).  
1.2 Develop a model algorithm and screening protocol for implementing PrEP by January 
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2020 by looking at policy in nursing algorithm, evidence-based practice and the 
recommendations of PrEP experts, clinicians, and staff.  
1.3 Produce the AYA ComPrEP kits. These are bags that contain freebies and educational 
materials on PrEP and HIV prevention similar to the Quit Smoking Kit being distributed by 
the San Francisco Department of Public Health.  
• CHPY Staff and Providers Trainings and Seminars. 
2.1 Conduct the AYA ComPrEP training seminar for CHPY clinicians and staff by 
March 2020. 
 2.2 Implement the risk assessment and screening tool in at least 2 CHPY clinics by 
April 2020.  
2.3 Create an online platform on PrEP, HIV and STI prevention that is accessible and 
user friendly for AYA patients March 2020. 
• Screening Tools and PrEP Protocol Implementation 
3.1 Implement the model algorithm (use of risk assessment and screening tool) in at 
least one CHPY clinic for 6-8 weeks by April 2020 
• Project Evaluation 
4.1 Evaluate the clinical staff and providers’ comprehension and comfort to initiate and 
prescribe PrEP 
 4.2 Evaluate the ‘AY ComPrEP’ by April/May 2020.  
C) How will this intervention change practice?  
This intervention will change practice by standardizing practice in CHPY clinics to improve 
clinicians and staff PrEP initiation and prescription to most-at-risk AYA patients, 
increase awareness and access of AYA patients to PrEP, and maintain 0% HIV 
infection rate among AYA patients on PrEP and condom use.  
D) Outcome measurements:  
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Post-training evaluation for clinicians and staff by April 2020: 
• At least 80% of the clinicians have increased knowledge and comfort to 
prescribe PrEP to its AYA patients  
• At least 80% of the clinicians who attended the training workshop have will 
have: 
o Increased knowledge on HIV and PrEP  
o Increased in enabling or non-stigmatizing attitudes on HIV and PrEP 
o Used the guidelines (e.g. risk assessment tool and protocol) in 
practice or demonstrated in the case studies simulation; and 
o Stated increased comfort in prescribing PrEP to AYA patients after 
the implementation/simulation. 
Post-AYA ComPrEP evaluation by April 2020: 
• 100% of the providers or staff were using the risk assessment in every patient 
screening over the 6-8 weeks period. Clinicians were able to decide how to measure 
risk.  
 
• 80% of the providers are satisfied with the implementation of the risk assessment and 
implementation of PrEP protocol (Feasibility of the risk assessment algorithm) 
 
 
To qualify as an Evidence-based Change in Practice Project, rather than a Research Project, the 
criteria outlined in federal guidelines will be used:  
(http://answers.hhs.gov/ohrp/categories/1569)  
☐   This project meets the guidelines for an Evidence-based Change in Practice Project as 
outlined in the Project Checklist (attached). Student may proceed with implementation. 
☐This project involves research with human subjects and must be submitted for IRB approval 
before project activity can commence. 
Comments:   
EVIDENCE-BASED CHANGE OF PRACTICE PROJECT CHECKLIST * 
 
Instructions: Answer YES or NO to each of the following statements: 
Project Title:  
 
YES NO 
The aim of the project is to improve the process or delivery of care with 
established/accepted standards, or to implement evidence-based change. There is no 




The specific aim is to improve performance on a specific service or program and is a 




The project is NOT designed to follow a research design, e.g., hypothesis testing or 
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cross-sectional, case control). The project does NOT follow a protocol that overrides 
clinical decision-making. 
The project involves implementation of established and tested quality standards 
and/or systematic monitoring, assessment or evaluation of the organization to ensure 
that existing quality standards are being met. The project does NOT develop 




The project involves implementation of care practices and interventions that are 
consensus-based or evidence-based. The project does NOT seek to test an 




The project is conducted by staff where the project will take place and involves staff 




The project has NO funding from federal agencies or research-focused organizations 




The agency or clinical practice unit agrees that this is a project that will be 
implemented to improve the process or delivery of care, i.e., not a personal research 
project that is dependent upon the voluntary participation of colleagues, students 




If there is an intent to, or possibility of publishing your work, you and supervising 
faculty and the agency oversight committee are comfortable with the following 
statement in your methods section:  “This project was undertaken as an Evidence-
based change of practice project at X hospital or agency and as such was not 





ANSWER KEY: If the answer to ALL of these items is yes, the project can be considered an 
Evidence-based activity that does NOT meet the definition of research.   
 
IRB review is not required.  Keep a copy of this checklist in your files.  If the answer to ANY 
of these questions is NO, you must submit for IRB approval. 
 
*Adapted with permission of Elizabeth L. Hohmann, MD, Director and Chair, Partners Human 
Research Committee, Partners Health System, Boston, MA.   
 
STUDENT NAME (Please print):  
 
_IGOR. MOCORRO, MPH, PHN, BSN, RN__________________________________ 
Signature of Student:  
______________________________________________________DATE__02/15/2019_        
 
SUPERVISING FACULTY MEMBER (CHAIR) NAME (Please print):   
 
__PRABJOT SANDHU, DNP, FNP-C, PA-C, CNL____________________________ 
Signature of Supervising Faculty Member (Chair):  
______________________________________________________DATE____________ 
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Appendix D. List of CHPY Clinics and Health Centers 
 
Community Clinics Location Services Offered Other 
Than Family Planning 
1) Cole Street Clinic 
*Currently offering PrEP 
Haight-Ashbury District Primary, Urgent Care 
2) Larkin Clinic 
*Currently offering PrEP 
Tenderloin Primary, Urgent Care 
3) Dimensions Clinic  Castro-Mission Primary Care 
4) Hawkins Clinic Sunnydale  
5) ACAC HIV Specialty Clinic Tenderloin Primary Care 
6) Third Street Clinic 3rd Street  
7) Special Program for Youth Juvenile Justice Center Primary, Acute 
8) New Generation Health Center Potrero Avenue Primary Care 
Women’s Health 
School-based Clinics   
9) Balboa Teen Center Balboa High School Primary Care 
10) Burton Teen Clinic Burton High School  
11) Willie Brown Middle School 
Health Center 
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Appendix F. Project Information for In-Depth Interview Participant 
 
 
Doctor of Nursing Practice – Family Nurse Practitioner 
School of Nursing and Health Profession | University of San Francisco  
 
In partnership with the Community Health Program for Youth 
San Francisco Department of Public Health  
 
Adolescent and Young Adult Comprehensive PrEP Education Project (AYA ComPrEP)  
By: Igor Mocorro, MPH, BSN, RN, PHN | USF DNP-FNP Cohort 2020 
 
PROJECT INFORMATION  
A. Purpose and Nature of the Assessment  
Under the supervision of Jodie Sandhu, DNP, FNP-BC, PA-C, and Stefan Rowniak, PhD, 
FNP-BC, Professors of the Doctor in Nursing Program of the University of San Francisco, and 
in partnership with the Community Health Program for Youth (CHPY) of the San Francisco 
Department of Public Health through its leadership Lori Kohler, MD, Carol Taniguchi, MSN, 
PNP-BC, and CHPY PrEP Champion/Coordinator Adam Leonard, MSN, PNP-BC, I, Igor 
Mocorro, MPH, RN, PHN, a student of the DNP-FNP of USF is conducting a needs assessment 
on the barriers and opportunities to support the creation of a school-based PrEP Program for 
adolescents in San Francisco, particularly at Balboa Teen Clinic.  
Ultimately, the main aim of this project is to increase our understanding of the needs of the clinic 
to support a successful school-based PrEP program to prevent HIV infections among 
adolescents/teens or students of Balboa High School and the clinic’s patients. The Community 
Health Program for Youth (CHPY) intends to use the information as a foundation for future 
endeavor in programmatic interventions on PrEP for adolescents. They will use data collected to 
design a PrEP educational program that will address the PrEP needs of AYA. There are a 
number of organizations campaigning for PrEP for adolescents and young adults; however 
barriers to PrEP in school-based setting in particular have not been a primary focus.  
You have been invited to participate because you are a member of the staff of a CHPY clinic 
who has expertise and knowledge about the current condition of the clinic for which you work. 
Also, you have connections with the patients whom we believe will benefit from the needs 
assessment and the AYA ComPrEP Project.  
B. Procedures and Processes Involved in Participating  
I would like to make it clear that your participation in this project is entirely voluntary. It is your 
choice whether to participate in it or not. If you choose to participate, you are also free not to 
answer any of the questions, and you can also decide to stop participating in the one-on-one 
interview at any time if you wish. However, we would greatly appreciate you letting us know the 
reason for not answering any question, or for withdrawing your participation, so that we can 
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improve our project methods.  
In terms of the process, if you choose to participate in this study, I will set up an interview. I will 
be recording the interview discussion with your permission. The interview will include questions 
about barriers and opportunities to PrEP implementation in your clinic such as ones about 
existing protocols and algorithms. The interview will take no more than one hour and half.  
By May 10, 2019, the report of my findings from this assessment will be complete. If you are 
interested, I am glad to send you the output of the project. You can also coordinate with the 
leadership of the Community Health Program for Youth for information on any future studies, 
projects, or programs that may come out of this assessment.  
C. Confidentiality and Potential Risks of Participating in the Study  
This project is taking every possible step to ensure confidentiality of any and all personal 
information on participants. I know that breaches of confidentiality could lead to problems for 
participants, so I have taken the following measures to avoid this from happening. 1) I do not 
write the name of the participant or his/her place of work (i.e. the in-depth who is providing us 
with information about his/her PrEP experiences in the clinic) on any paper that would allow 
someone to link the gathered information to him/her. 2) Names of participants and other 
identifying information will not appear in any published reports or presentations about this 
assessment. All forms used in this project will be stored in a locked cabinet or cupboard to which 
only the project team/committee has access. These data will be destroyed as soon as they are no 
longer needed.  
D. Discomfort that you might experience as a participant  
The interview includes questions that may make you feel uncomfortable at times, and it may 
bring up topics that are difficult to talk about. It is not my intention to make you uncomfortable. I 
want you to know that you do not have to answer any question or take part in the interview at all 
if you feel the questions are overly personal or if talking about the topic makes you 
uncomfortable.  
E. Potential Benefits for you and the community in relation to your Participation  
There will be no direct benefit to you for participating in this study. However, I hope that your 
involvement will be interesting for you, as it might shed some light on some issues/concerns you 
may have, and also on rewards that you experience in working at this clinic. I also hope that you 
will learn from the interview process and from any discussions, which may arise as a result of 
doing it. Through these interviews with the staff members of the clinic, we hope to be able to 
gather rich and valuable information that will assist CHPY and other local and national efforts to 
understand the needs of adolescents and young adults in school-based setting to access PrEP 
services and HIV education for the prevention of HIV.  
F. Cost and Compensation  
There will be no cost for you to participate in this research. If you decide to participate in the 
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study, I will provide you with a gift card as an appreciation of your time and effort.  
G. Alternatives  
You are free to choose not to participate in this project without any effect on your future status 
with USF and CHPY.  
H. Questions  
You have spoken to me Igor Mocorro, a DNP-FNP student of USF. I would like to make sure 
that you are voluntarily willing to participate in this quality improvement project assessment and 
that you have obtained all the information that you need in order to make an informed choice 
about your participation. If this information sheet contains words that you do not understand 
please ask me and I will take time to explain. You do not have to decide today whether or not 
you will participate in the interview. Before you make a decision, you can talk to anyone you 
would like to about doing this interview.  
If you have any further questions about this assessment that I cannot answer or you have 
comments or complaints about the interview, you may contact my professors Jodie Sandhu at 
pksandhu@usfca.edu, and Stefan Rowniak at srrowniak@usfca.edu. 
CONSENT  
You have been given a copy of the information sheet and participation form to keep.  
PARTICIPATION IN THIS QI PROJECT ASSESSMENT IS VOLUNTARY. You are 
free to decline to participate in assessment, or to withdraw your participation at any point, 
without penalty. Your decision about whether or not to participate in this process will have 
no influence on your present or future status at the University of San Francisco, and the 
Community Health Program for the Youth. 
I have read and understand the information on the information sheet, or it has been read to me. I 
have had the opportunity to ask questions related to this assessment, and any questions I have 
asked have been answered to my satisfaction. I voluntarily participate in this project and 
understand that I have the right to end the interview at any time.  
Signature/initial of participant: ________________________________  
Signature/initials of interviewer: ________________________________  
Date of interview: _________________________________  
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Appendix G. In-Depth Interview Questionnaire 
 
Doctor of Nursing Practice – Family Nurse Practitioner 
School of Nursing and Health Profession | University of San Francisco  
 
In partnership with the Community Health Program for Youth 
San Francisco Department of Public Health  
 
Adolescent and Young Adult Comprehensive PrEP Education Project (AYA ComPrEP)  
By: Igor Mocorro, MPH, BSN, RN, PHN | USF DNP-FNP Cohort 2020 
 
  CODE: __________________________________________________ 
  Place/location: ___________________________________________ 
  Date and Time: ___________________________________________ 
  Survey Questionnaire Facilitator: _____________________________ 
 
Assessment Tool: 
In-Depth Interview for CHPY Staff 
Introduction  
Good morning/afternoon. I would like to thank you for taking the time to meet with me and to 
share your opinions and expertise on this subject. My name is Igor Mocorro. I am a graduate 
student in the Doctor of Nursing Practice – Family Nurse Practitioner at the University of San 
Francisco. I am working with the Community Health Program for the Youth (CHPY) on this 
project.  
I believe that you have received the information of this project ahead of time/before this meeting. 
If you have any questions, we can talk about them while we go through the Study Information 
and Participation forms. I will need to get your agreement before I start the interview and make 
sure that all of your questions and concerns are addressed. 
 
Briefly discuss with the interviewee the Study Research Information/Participation Forms and 
obtain their agreement to proceed with the interview. 
I understand that you may need to take a break from the interview. Please don't hesitate to let me 
know if you need that. Do you have any questions before I start?  
I also just wanted to let you know that I look at PrEP as a pill to take daily; an effective 
preventive tool for HIV infection for people who are at risk of HIV infection. Currently, 
tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) also known as Truvada™ is the 
only pharmaceutical interventions in oral form that shown in clinical trials to prevent HIV 
transmission that has approval by the FDA, including to adolescents. Do you have any questions 
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before we start? 
 
Questions:  
I. Introduction  
1. How long have you been working in this clinic or with CHPY?  
2. How would you describe your overall experience working at CHPY?  
3. Please describe how you feel about the care being provided at this clinic or at CHPY in 
general.  
4. How do you feel about the PrEP services, resources and programs offered at CHPY?  
II. General Attitude about HIV and PrEP 
1. What do you think of HIV and AIDS?  
2. In what way do you think HIV and AIDS affects the lives of adolescents and young 
adults?  
3. What do you think about PrEP?  
4. What are your views about adolescents taking PrEP? 
5. To what extent do you feel comfortable discussing sexuality, sexual health, HIV, and 
HIV prevention services such as PrEP with your clients or patients? Why? Why not?  
6. To what extent do you feel comfortable discussing HIV and PrEP in a school-based 
setting? 
III. Experiences of PrEP   
1. How do staff or clinicians here approach patient’s HIV risk?  
a. Please explain how important is it for you to screen every patient on HIV risk.  
 
2. With regard to PrEP services, do you think adolescents are treated differently?  
a. And if so how?  
 
3. What do you appreciate about the current HIV prevention services offered at CHPY?  
a. What, if any, policies/regulations/practices regarding HIV prevention and PrEP at 
CHPY seem to work well?  
 
4. What challenges/problems if any have you found in providing HIV prevention services at 
CHPY? How about with PrEP? 
IV. Programs and Services  
1. If you identify a client who is at risk for HIV infection in this clinic, what do you usually 
do? What opportunities would you have to help the client reduce his/her risk? 
a. What sort of support from colleagues is available for you?  
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b. What might the barriers be in developing a PrEP Program in this clinic?  
2. What information or educational programs have been provided to clients or patients in 
this clinic about HIV and AIDS? How about PrEP?  
 
a. Have you participated in any of these programs? Why or why not?  
b. Has the clinic informed clients about their risk?  
 
3. How available are safer sex supplies such as condoms and lubrication here in this clinic?  
 
4. What type of prevention materials such as pamphlets, flyers, posters, videos, or websites 
do you think you are allowed to provide to clients in this clinic?  
 
a. Would you feel comfortable having or using such things here in this clinic?  
 
5. Would you know what to say to a client who experiences side effects from taking PrEP? 
 
6. Would you know what to do if a client decided to stop his/her PrEP intake?  
V. Moving Forward/ Conclusion  
1. What general changes could be implemented in the facility to better support your knowledge 
and skills of HIV prevention, particularly on PrEP?  
1. What could the CHPY management or leadership do to better support your PrEP services 
in this clinic?  
2. What facility policies could be implemented to better support PrEP for adolescents in this 
clinic? 
Closing  
< Summary of interview outcomes >.  
In the next few weeks, we will be analyzing the data from this and the other interviews we are 
conducting with other staff. Would it be alright for me to contact you if I have further questions? 
Likewise, if you are interested in getting a recording of this interview, we can send it to you. As 
an appreciation of your time and efforts participating in this study, I have some 
educational/informational materials for you (or other incentives, etc.).  
I will be designing a program plan and implement by Spring 2020. The product of this 
assessment and project will be presented to USF by May 2020 and to CHPY as well. If you are 
interested in learning about the outcome of this assessment and the project, please let me know.   
Thank you again for your participation in this project. The information you provided will be very 
useful as we move forward with PrEP implementation at Balboa Teen Clinic. If you need to 
contact me, please feel free to do so at any time. I wish you good health and a happy life.  
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n= 9 staff participated in the in-depth interviews, all works at Balboa Teen 
Health Center  
 
6 participants were CHPY staff  
3 participants were SFUSD staff  
 
Attitudes about 
HIV and PrEP 
• All participants wanted to have PrEP services available at Balboa Teen 
Health Center.  
• Everyone was excited about the project. Everyone believed that bringing 
PrEP to Balboa will increase awareness 
 
“In high school, you want young people to have that sense of self care and 
be proactive about their health.” 
 
“I am concerned about students, we show them the AIDS quilt but young 
people do not understand…. Risky behaviors start to increase because some 
students, their education have gaps of this HIV information.”  
 
“We have a parent who called us asking about why we provide birth control 
to her daughter. It was hard. It could be the same problem  with PrEP .” 
 
‘The thought that this will be the first school-based PrEP in California, one 





• 2 out of 9 clinic staff and team members attended a training on PrEP 
previously 
• Others learned about PrEP through TV ads, word of mouth, meetings 
 
PrEP Program & 
Services at 
Balboa Clinic 
• Each team member has a role to take in this initiative. There is a need to 
clarify or communicate roles. 
• There is a disconnect between PrEP navigator & clinic staff 
 
• HIV screening & confidentiality –Staff were aware of their roles in 
screening, education, counseling, monitoring/follow-up 
• Clinic members voiced out the need for materials on PrEP, including 
presentation materials about PrEP for AYA for teachers, staff, students, and 
patients.  
 
“We [CHPY & SFUSD] have a great partnership. I am glad that DPH is 
here.” 
 
“I feel I am in the outside but I am willing to learn and be a part of this 
initiative.”  





• Staff members needed education, training, and workshop both for first 
timer and as a refresher for those who had a PrEP training previously 
before seeing patients in the clinic for PrEP outreach, education/counseling 
and PrEP prescription; 
• The clinic need good outreach and dissemination strategies to reach 
communities and potential patients of PrEP services in Balboa 
 
“We had resistant from some people. If somebody tested positive, what do we 
do with that? At what point can we educate the student enough to have safe 
communication to bring parents to the conversation.”  
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Appendix I. AYA ComPrEP Project Gantt Chart 















































































PROJECT DEVELOPMENT                           
Evidence Research 
Sept 2018 Oct 2018 
 
100% X X               
 
    
  
Baseline Assessment 
Oct 2018 Feb 2019 
 
100%  X X X X X    X X           
  
Statement of Determination 
Oct 2018 June 2019 
 
100%  X X X      X       
 
    
  
Consultation with CHPY Leaderships 
Oct 2018 July 2019 
 
100%  X X X X X    X X X X X X  
 
    
  
INTERVENTION DEVELOPMENT & PLANNING   
 
                     
  
Consultations with PrEP Experts 
Feb 2019 July 2019 
 
100%      X X X    X X X   
 
    
  
In-Depth Interviews 
Dec 2019 Jan 2020 
 
100%                X X     
  
Creation of Screening Tools 
Dec 2019 Feb 2020 
 
100%                X X X    
  
Creation of AYA ComPrEP kits/binders 
Jan 2020 Feb 2020 
 
100%                 X X    
  
Creation of PrEP training and workshop modules 
Jan 2020 April 2020 
 





                
 
    
  
Education and Training of Staff 
April 2020 April 2020 
 
100%                 
 
  X  
  
Evaluation of training and education 
April 2020 April 2020 
 
100%                 
 
  X  
  
Implementation of screening tools 
April 2020 April 2020 
 
100%                 
 





                
 
    
  
AYA ComPrEP Evaluation 
April 2020 May 2020 
100% 
                   X X 
  
Dissemination of project results and outcomes 
May 2020 July 2020 
80% 
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Appendix J. Work Breakdown Structure 
 
1.0 Design  
1.1 Develop Project Scope  
1.2 Needs Assessment/Gap Analysis  
1.3 Develop Objectives  
1.4 Identify Key Stakeholders  
1.5 Develop Project Charter  
1.6 Submit Project Charter  
 
2.0 Plan  
2.1 Identify Project Team  
2.2 Discussion of Roles  
2.3 Develop Project Plan  
2.4 Develop WBS  
2.5 Develop Surveys  
2.6 Prepare Staff Training Protocol  
 
3.0 Intervention  
3.1 Feasibility Analysis  
3.1.1 Site Survey   
3.1.2 Review/Observation of Clinic Workflow 
3.1.3 In-depth interviews 
3.2 Review and Develop Screening Tools, Protocols, and Algorithms   
3.3 PrEP Training Workshop  
3.3.1 Module 1  
3.3.2 Module 2 
3.3.3 Module 3 
3.3.4 Module 4 
3.4 Identify Funding Sources  
 
4.0 Results 4.1 Present Results of Assessment to CHPY and Balboa Teen Health Center Staff 
4.1.1 Analyze Survey Findings  
4.1.2 Summarize Findings  
 
5.0 Evaluation  
5.1 Identify Results of Knowledge, Attitudes, and Confidence to Prescribe PrEP 
5.2 Review Training Feedback  
5.3 Write Final Report  
5.4 Dissemination  
5.4.1 DNP Paper  
5.4.2 DNP Presentation 
 
 
PROJECT OVERVIEW PAPER   106 
Appendix K. Communication Matrix 
 
Stakeholder  Project Role  Item/Event  Special Instructions  
Lori Kohler, MD 
Carol Taniguchi, NP  
Authorization  
Change in practice 
approval  
Review and approve project 
and screening tool intervention  
DNP Chairs: Dr. Prabjot 
Sandhu  
DNP committee: Dr. 
Stefan Rowniak  
Authorization, 




DNP project approval  
Assist and support with 
development and approval of 
DNP project.  
DNP Committee 
Adam Leonard, NP 
Supervision and 
guidance of project  
Change in practice: HIV 
risk screening protocol  
  
Provide supervision, 
assistance, and support for 
development of project.  
DNP author/Project 
manager: Igor Mocorro  
Project developer, 
manager, and evaluator  
Change in practice: HIV 
risk screening protocol  
 
Develop, implement, and 
evaluate HIV risk screening 
protocol to optimize PrEP 
implementation.  
EHR system consultant, 
clinical data specialist, and 
USF health informatics 
student intern  
EHR system navigation  
Baseline clinical data 
assessment, electronic 
screening tool  
Assist with use of EHR system 
to conduct baseline clinical 
data assessment, and with 
integration of the screening 
tool into the EHR.  
PrEP case manager  Intervention design  Change in practice  
Provide input for designing 
appropriate HIV-risk screening 
protocol.  
Gilead Sciences assistant 
director of medical 
sciences for the West Coast 
region, and local 
representative  
Intervention design  Change in practice  
Provide input for designing 
appropriate HIV-risk screening 
protocol.  
San Francisco City Clinic Intervention design  Change in practice  Provide input for designing 
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and SFDPH CHPY 
managers  
appropriate HIV risk screening 
protocol.  
City Wide PrEP NP  
Intervention design, 
clinical staff education, 
and potential 
dissemination  
Change in practice  
Provide input for designing 
appropriate HIV risk screening 
protocol, assist with clinical 
staff education, and potentially 
disseminate protocol to other 
primary care clinics in SF.  
Clinic providers and staff 
(MD, NPs, RNs, MAs, 
clinic operations manager, 
director of nursing)  
Intervention recipients  Change in practice  
Learn and follow HIV-risk 
screening protocol to increase 
identification of patients at risk 
for acquiring HIV and increase 
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• Compassionate and culturally 
sensitive environment   
• Small organizational size   
• FPACT reimbursement 
• Patient population represents at-risk 
 population eligible for PrEP   
• Chief medical officer and lead 





• No standardized protocols  
• Many changes to clinic workflow  





• At-risk patient population   
• FDA approval of Truvada as PrEP 
for adolescents   
• EHR changing from eCW to Epic in 
2019   
• Mutual goal to improve patient 
outcomes in HIV prevention   
• Opportunity for CHPY and SFDPH 
leadership in conjunction with new 






• Potential patient refusal of PrEP   
• Cultural stigma   
• Financial cost of PrEP  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Appendix M. AYA ComPrEP Budget Summary 
 
 
Cost to Implement the AYA ComPrEP 
Staff leader for 
implementation  
Estimated hourly wage 








be spent on 
project 
implementation  
Subtotal cost (FTE)  







$30 9 interviews $270.00 
PrEP Kits/Binder $20.00 Cost per Kit 15 kits $300.00 
Evaluation Tools   $90.00 
Estimated cost  
 
$660.002 
(Excluding the Project Manager 
cost which is taken through the 
SFDPH salary) 
1Project manager wage estimate based on average salary for project manager consultant in San 
Francisco reported by Glassdoor. Retrieved from https://www.glassdoor.com/Salaries/project-
management-consultant-salary-SRCH_KO0,29.htm  
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Appendix N. Cost-Benefit Estimate 
 
 
HIV management costs  
 
HIV PrEP (Benefits)  
 
Estimated HIV management lifetime cost: 
$480,000 
Annual: $20,000+ per year  
 
Estimated PrEP cost:  
$13,000 per patient per year  
 
Estimated total cost of HIV management for 5 
years: $100,000  
 
Estimated total cost of PrEP for 5 years: $65,000 
 
1Centers for Disease Control and Prevention. (2015). HIV cost effectiveness. Retrieved from 
http://www.cdc.gov/hiv/programresources/guidance/costeffectiveness/index.html  




























Appendix O. PrEP Tool – California Department of Public Health 
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Appendix R. Agenda of PrEP Training 
 
PrEP Education Training Workshop for Nurse Practitioners 
April 18, 2020 
 
Time Agenda 
9:00 AM – 9:15 AM Introduction/Overview/Pre-Survey 
9:15 AM – 10:00 AM Module 1: STI and HIV Review 
10:00 AM– 11:00 AM Module 2: Key Elements for Ethical and Effective HIV Prevention 
Counseling Practices  
11:00 AM – 11:15 AM BREAK 
11:15 AM – 12:30 PM Module 3: Adolescents, Reproductive Health & SOGI 
12:30 PM – 1:00PM WORKING LUNCH BREAK 
PrEP Support with Lyric (PrEP Navigation) 
1:00 PM – 1:45 PM Module 4: Pre-Exposure Prophylaxis 
1:45 PM – 3:00 PM Case Studies  
(25 minutes group work) 
(40 minutes Debrief/Post-Survey) 
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Appendix S. Module 1: The Basic of STI, HIV & AIDS 
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Appendix T. Module 3: Key Elements for Ethical and Effective HIV Prevention Counseling 
Practices 
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Appendix U. Module 3: Adolescents, Reproductive Health, and SOGI 
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Appendix V. PrEP Training Workshop Module 4 
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Appendix W. Pre-Training Workshop Survey 
 
 
Doctor of Nursing Practice – Family Nurse Practitioner 
School of Nursing and Health Profession | University of San Francisco  
 
Initiating PrEP in Primary Care: Addressing the AYA High-Risk Populations 
Pre-Training Workshop Survey 
 
Section I. Information About You 
Direction: Please put a check on the box next to your answer on questions. Some of the other 
questions ask for answers in the form of written answers. 
 
1. First and Last Name: ____________________________ 
2. What is your DNP Track: _________________________ 
3. Year of Birth:  ____________ 
4. What is your gender? ___ Male    ___ Female    ___ Transgender    ___ Other Identification  
5. What is your sexual orientation: _____ Asexual    _____ Bisexual     _____ Homosexual/Gay 
_____ Heterosexual/Lesbian     _____Homosexual      ___ Pansexual      _____Queer 
___ Other; Specify: _______________                           ___ Prefer not to answer 
6. Have you attended a PrEP training before? _____ Yes; Describe: ____________________ 
_______________________________________________________________    _____ No  
7. Do you have experience providing PrEP services to clients?  _____ Yes; Describe: _______ 
_______________________________________________________________    _____ No 
8. Do you have any experience working on HIV issues in the past? _____ Yes; Describe: _____ 
_______________________________________________________________    _____ No 
 
Section II. Knowledge About HIV and PrEP 
Direction: True or False. Please put a check on the line next to your answer on questions. 
   
1. HIV is preventable.      _____ True     _____False 
2. HIV infection is curable. A person infected with HIV can access cure at treatment clinics 
or hospitals.     _____ True     _____False 
3. There is a vaccine available to prevent HIV infection.     _____ True     _____False 
4. Children born to HIV-positive women are infected with HIV at birth.      
     _____ True     _____False 
5. After a needle prick injury with a needle from an HIV-infected person, the chance of 
contracting HIV is less than 1%.     _____ True     _____False 
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6. After a needle prick injury with a needle from an HIV-infected patient, immediately 
gently expressing blood from the puncture site reduces the risk of contracting HIV 
infection.     _____ True     _____False 
7. After a needle prick injury with a needle from an HIV-infected person, a health worker 
may take HIV medications to reduce the chance of contracting HIV infection.      
     _____ True     _____False 
8. One can be identified as HIV-positive by the way the person looks (e.g. signs and 
symptoms like skin ulcers, weight loss).     _____ True     _____False 
9. If a person has a sexually transmitted infection (STI), his/her chance of getting HIV is 
higher.     _____ True     _____False 
10. A person will automatically get infected with HIV once he/she has sexual intercourse 
with a person living with HIV.     _____ True     _____False 
11. A person with HIV who is undetectable is considered infectious. He/she is likely to 
transmit the virus to his/her partners through sexual intercourse.      
     _____ True     _____False 
12. Daily PrEP can prevent HIV transmission through sex for up to more than 90%. 
     _____ True     _____False 
13. Daily PrEP can reduce the risk of acquiring HIV among people who inject drugs by 30%. 
     _____ True     _____False 
14. For PrEP to be effective against HIV infection should be taken once daily and should be 
taken continuously for 7 days before engaging in vaginal sex.  
      _____ True     _____False 
15. Using condoms can prevent HIV transmission and other STIs.  
     _____ True     _____False 
16. The use of condoms should be promoted to prevent HIV infection.  
     _____ True     _____False 
17. The use of condoms should not be promoted if a person is on PrEP.      
     _____ True     _____False 
18. A person who is at high risk for HIV and other STIs should be tested once a year for 
HIV.     _____ True     _____False 
19. A person who has no sexual partner is not at risk for HIV. He/she should never be tested 
for HIV.     _____ True     _____False 
20. Heterosexual men and women are not at risk for HIV infection and are not recommended 
for PrEP.     _____ True     _____False 
21. There is no alternative to daily dosing of PrEP. Other PrEP dosing is ineffective to 
prevent HIV transmission.     _____ True     _____False 
22. There is only one PrEP regimen available in the market to prevent HIV infection so it is 
easy to prescribe.     _____ True     _____False 
 
 
Section III. Enabling or Non-Stigmatizing Attitudes 
Direction: The following items are intended to measure people's opinions about issues 
surrounding HIV and AIDS and PrEP for adolescents. Responses will be used to gauge the 
enabling versus stigmatizing attitudes related to HIV and PrEP.  
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Disagree 
In my opinion, persons living with 
HIV deserve their illness. 
     
People who are HIV positive should 
be encouraged to keep their diagnosis 
to themselves. 
     
People who test positive for HIV 
should not engage in any sexual 
activity. 
     
I am uncomfortable providing 
care for an HIV infected person. 
     
A person who is HIV positive should 
not be allowed to work as a health 
worker. 
     
I have the right to know the HIV 
status of the patients/clients in our 
practice/unit/department, including 
those who are not under my care. 
     
I am willing to work in the same 
unit/office with a colleague who is 
HIV-positive. 
     
Health care workers should be 
required for an HIV antibody test 
before engaging in any hospital or 
clinical practice. 
     
I have the right to know if someone 
in our workplace is HIV-positive. 
     
Homosexual men should be allowed 
to donate blood. 
     
Condoms are for married people 
only. Adolescents should be 
prohibited from using condoms. 
     
A person who is HIV-positive should 
be mandated to tell their partners 
about their HIV status. 
     
As a professional health worker, I 
have the duty to educate the public on 
HIV and PrEP. 
     
It is embarrassing to talk about sex 
and condom use to clients; therefore, 
I should not initiate to talk about it 
with my clients or patients. 
     
Adolescents and young adults, 
including those below 18 years of 
age, who are at high risk of HIV 
infection, should be offered PrEP. 
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Parents of adolescents, particularly 
those below 18 years of age, who are 
on PrEP should always be involved in 
their care. 
     
Counseling should be a part of any 
PrEP program. 
     
Same-Day PrEP should be made 
available and offered to adolescents 
at-risk for HIV. 
     
Alternative PrEP dosing such as 
event-based dosing should be made 
available to adolescents. 
     
Non-clinician staff (nurses, medical 
assistants, health workers) should 
take an active role in adolescents 
PrEP follow-up and monitoring. 
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Appendix X. Post-Training Workshop Evaluation 
 
 
Doctor of Nursing Practice – Family Nurse Practitioner 
School of Nursing and Health Profession | University of San Francisco  
 
Initiating PrEP in Primary Care: Addressing the AYA High-Risk Populations 
Post-Training Workshop Evaluation Survey 
 
Section I. Information About You 
Direction: Please put a check on the box next to your answer on questions. Some of the other 
questions ask for answers in the form of written answers. 
 
1. First and Last Name: ____________________________ 
2. What is your DNP Track: _________________________ 
3. Year of Birth:  ____________ 
4. What is your gender? ___ Male    ___ Female    ___ Transgender    ___ Other Identification  
5. What is your sexual orientation: _____ Asexual    _____ Bisexual     _____ Homosexual/Gay 
_____ Heterosexual/Lesbian     _____Homosexual      ___ Pansexual      _____Queer 
___ Other; Specify: _______________                           ___ Prefer not to answer 
 
 
Section II. Evaluation of Presentations & Simulation Activities 
Direction: Select all that apply. Please put a check on the line before your answer on 
question/statement. Some of the other questions ask for answers in the form of written answers. 
 
As a result of participating in the session "Module 1: The Basic of STI, HIV and AIDS," I am 
able to: 
_____ Define and differentiate STI, HIV, and AIDS 
______ Understand how HIV is transmitted from one person to another 
______ Correct misconceptions about HIV transmission 
______ Understand how HIV affects the body 
______ Learn how HIV and AIDS can be prevented as well as treated and managed 
 
 
As a result of participating in the session "Module 2: Key Elements for Ethical and Effective 
HIV Prevention Counseling Practices," I am able to: 
______ Describe the importance of HIV counseling 
______ Identify the DOs and DONTs of HIV prevention counseling 
______ Describe key points in PrEP counseling 
______ Describe what is provider-initiated counseling and Testing (PICT) 
_______ Describe what is client-initiated counseling and Testing (CICT) 
 
As a result of participating in the session "Module 3: AYA and The SOGI Initiative," I am better 
able to: 
______ Describe the characteristics of adolescents and young adults (AYA), and transgender 
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AYA 
______ Identify the health risks and solutions for AYA 
______ Describe the difference of sex, sexual orientation, and gender identity. 
______ Assess, plan, and intervene for an AYA client who may visit to our clinic for primary 
care 
 
As a result of participating in the session "Module 4: Pre-Exposure Prophylaxis for AYA," I am 
able to: 
______ Describe what PrEP is, medication available, and its indication. 
______ Describe PrEP effectiveness, side effects, and benefits. 
______ Identify the barriers of PrEP use in adolescents and young adults. 
______ Understand PrEP resources, guidelines, and algorithm. 
______ Develop confidence to prescribe PrEP in our practice 
 
 







Presenter: Igor Mocorro, MPH, RN, 
PHN. This speaker's presentation 
skills were effective for the content 
presented. 
 
     
Overall, I believe my knowledge and 
confidence to prescribe PrEP to 
adolescents and young adults in my 
practice has increased. 
 
     
 
 
List at least 3 changes that you will initiate in your practice related to advancing the health of 










Section III. Knowledge About HIV and PrEP 
Direction: True or False. Please put a check on the line next to your answer on questions. 
   
1. HIV is preventable.      _____ True     _____False 
2. HIV infection is curable. A person infected with HIV can access cure at treatment clinics 
or hospitals.     _____ True     _____False 
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3. There is a vaccine available to prevent HIV infection.     _____ True     _____False 
4. Children born to HIV-positive women are infected with HIV at birth.       
     _____ True     _____False 
5. After a needle prick injury with a needle from an HIV-infected person, the chance of 
contracting HIV is less than 1%.     _____ True     _____False 
6. After a needle prick injury with a needle from an HIV-infected patient, immediately 
gently expressing blood from the puncture site reduces the risk of contracting HIV 
infection.     _____ True     _____False 
7. After a needle prick injury with a needle from an HIV-infected person, a health worker 
may take HIV medications to reduce the chance of contracting HIV infection.      
     _____ True     _____False 
8. One can be identified as HIV-positive by the way the person looks (e.g. signs and 
symptoms like skin ulcers, weight loss).     _____ True     _____False 
9. If a person has a sexually transmitted infection (STI), his/her chance of getting HIV is 
higher.     _____ True     _____False 
10. A person will automatically get infected with HIV once he/she has sexual intercourse 
with a person living with HIV.     _____ True     _____False 
11. A person with HIV who is undetectable is considered infectious. He/she is likely to 
transmit the virus to his/her partners through sexual intercourse.      
     _____ True     _____False 
12. Daily PrEP can prevent HIV transmission through sex for up to more than 90%. 
     _____ True     _____False 
13. Daily PrEP can reduce the risk of acquiring HIV among people who inject drugs by 30%. 
     _____ True     _____False 
14. For PrEP to be effective against HIV infection should be taken once daily and should be 
taken continuously for 7 days before engaging in vaginal sex.  
      _____ True     _____False 
15. Using condoms can prevent HIV transmission and other STIs.  
     _____ True     _____False 
16. The use of condoms should be promoted to prevent HIV infection.  
     _____ True     _____False 
17. The use of condoms should not be promoted if a person is on PrEP.      
     _____ True     _____False 
18. A person who is at high risk for HIV and other STIs should be tested once a year for 
HIV.     _____ True     _____False 
19. A person who has no sexual partner is not at risk for HIV. He/she should never be tested 
for HIV.     _____ True     _____False 
20. Heterosexual men and women are not at risk for HIV infection and are not recommended 
for PrEP.     _____ True     _____False 
21. There is no alternative to daily dosing of PrEP. Other PrEP dosing is ineffective to 
prevent HIV transmission.     _____ True     _____False 
22. There is only one PrEP regimen available in the market to prevent HIV infection so it is 
easy to prescribe.     _____ True     _____False 
 
 
Section IV. Enabling or Non-Stigmatizing Attitudes 
Direction: The following items are intended to measure people's opinions about issues 
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surrounding HIV and AIDS and PrEP for adolescents. Responses will be used to gauge the 
enabling versus stigmatizing attitudes related to HIV and PrEP.  
 







In my opinion, persons living with HIV 
deserve their illness. 
     
People who are HIV positive should be 
encouraged to keep their diagnosis to 
themselves. 
     
People who test positive for HIV 
should not engage in any sexual 
activity. 
     
I am uncomfortable providing care for 
an HIV infected person. 
     
A person who is HIV positive should 
not be allowed to work as a health 
worker. 
     
I have the right to know the HIV status 
of the patients/clients in our 
practice/unit/department, including 
those who are not under my care. 
     
I am willing to work in the same 
unit/office with a colleague who is 
HIV-positive. 
     
Health care workers should be 
required for an HIV antibody test 
before engaging in any hospital or 
clinical practice. 
     
I have the right to know if someone in 
our workplace is HIV-positive. 
     
Homosexual men should be allowed to 
donate blood. 
     
Condoms are for married people only. 
Adolescents should be prohibited from 
using condoms. 
     
A person who is HIV-positive should 
be mandated to tell their partners about 
their HIV status. 
     
As a professional health worker, I have 
the duty to educate the public on HIV 
and PrEP. 
     
It is embarrassing to talk about sex and 
condom use to clients; therefore, I 
should not initiate to talk about it with 
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my clients or patients. 
Adolescents and young adults, 
including those below 18 years of age, 
who are at high risk of HIV infection, 
should be offered PrEP. 
     
Parents of adolescents, particularly 
those below 18 years of age, who are 
on PrEP should always be involved in 
their care. 
     
Counseling should be a part of any 
PrEP program. 
     
Same-Day PrEP should be made 
available and offered to adolescents at-
risk for HIV. 
     
Alternative PrEP dosing such as event-
based dosing should be made available 
to adolescents. 
     
Non-clinician staff (nurses, medical 
assistants, health workers) should take 
an active role in adolescents PrEP 
follow-up and monitoring. 
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Appendix Y. Clinicians Knowledge on HIV and AIDS, and PrEP (n=19) 
Knowledge Items Correct Responses (%) 
Pre-Test Post Test 
HIV is preventable. (T) 19 (100) 19 (100) 
Daily PrEP can prevent HIV transmission through sex for up to more 
than 90%. (T) 
19 (100) 19 (100) 
The use of condoms should be promoted to prevent HIV infection. (T) 19 (100) 19 (100) 
The use of condoms should not be promoted if a person is on PrEP. (F) 19 (100) 19 (100) 
If a person has a sexually transmitted infection (STI), his/her chance of 
getting HIV is higher. (T) 
18 (95) 19 (100) 
Heterosexual men and women are not at risk for HIV infection and are 
not recommended for PrEP. (F) 
18 (95) 19 (100) 
A person who has no sexual partner is not at risk for HIV. He/she should 
never be tested for HIV. (F) 
17 (89) 19 (100) 
Using condoms can prevent HIV transmission and other STIs. (T) 16 (84) 19 (100) 
Truvada is the only PrEP regimen available in the market to prevent 
HIV infection so it is easy to prescribe PrEP. (F) 
11 (58) 19 (100) 
There is no alternative to daily dosing of PrEP. Other PrEP dosing is 
ineffective to prevent HIV transmission. (F) 
10 (53) 19 (100) 
HIV infection is curable. A person infected with HIV can access cure at 
treatment clinics or hospitals. (F) 
17 (89) 18 (95) 
After a needle prick injury with a needle from an HIV-infected person, a 
health worker may take HIV medications to reduce the chance of 
contracting HIV infection. (T) 
16 (84) 18 (95) 
One can be identified as HIV-positive by the way the person looks (e.g. 
signs and symptoms like skin ulcers, weight loss). (F) 
17 (89) 18 (95) 
A person will automatically get infected with HIV once he/she has 
sexual intercourse with a person living with HIV. (F) 
18 (95) 18 (95) 
There is a vaccine available to prevent HIV infection. 18 (95) 17 (89) 
After needle prick injury with a needle from an HIV-infected person, the 
chance of contracting HIV is less than 1%. 
13 (68) 17 (89) 
Children born to HIV-positive women are infected with HIV at birth. 15 (79) 16 (84) 
A person with HIV who is undetectable is considered infectious. He/she 
is likely to transmit the virus to his/her partners through sexual 
intercourse. 
7 (37) 12 (63) 
A person who is at high risk for HIV and other STIs should be tested 
once a year for HIV. 
0 (0) 11 (58) 
After needle prick injury with a needle from an HIV-infected patient, 
immediately gently expressing blood from the puncture site reduces the 
risk of contracting HIV infection. 
9 (47) 11 (58) 
Daily PrEP can reduce the risk of acquiring HIV among people who 
inject drugs by 30%. 
4 (21) 7 (37) 
For PrEP to be effective against HIV infection should be taken once 
daily and should be taken continuously for 7 days before engaging in 
vaginal sex. 
4 (21)  7 (37) 
 
